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Abstract 
 
Endotoxins, or Lipopolysaccharides (LPS) present on the surface of Gram negative 
bacteria play a key role in the pathogenesis of septic shock, a common clinical 
problem and a leading cause of mortality in critically ill patients, for which no 
specific modalities are available at the present time. The toxic moiety of LPS is a 
glycolipid called Lipid A, which is composed of a bis-phosphorylated diglucosamine 
backbone bearing up to seven acyl chains in ester and amide linkages. Lipid A is 
structurally highly conserved in Gram negative bacteria, and is therefore an attractive 
target for developing anti-endotoxin molecules designed to sequester, and thereby 
neutralize, the deleterious effects of endotoxin.   
The anionic and amphipathic nature of Lipid A enables the interaction of a wide 
variety of cationic amphiphiles with the toxin. A systematic evaluation of several 
structural classes of cationic amiphiphiles both peptidic and non-peptidic small 
molecules, in the broader context of recent efforts aimed at developing novel anti-
endotoxin strategies. The derivation for the pharmacophore for LPS recognition has 
led to the identification of novel, nontoxic, structurally simple molecules, the 
lipopolyamines. The lipopolyamines bind and neutralize LPS in in vitro experiments 
as well as in animal models of endotoxicity, and thus present novel and exciting leads 
for rational, structure-based development of LPS sequestering agents of potential 
clinical value.    
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Chapter 1 
Introduction: Sepsis 
1.1 Background 
Gram-negative sepsis, or "blood poisoning" in lay terminology, is a common and 
serious clinical problem. While fewer than 100 cases were reported prior to 19201, it 
is now the thirteenth leading cause of overall mortality2 globally, and the number one 
cause of deaths in the intensive care unit3 accounting for some 200,000 fatalities in 
the US annually4 (Figure 1). While the incidence continues to rise worldwide5;6 due 
to increased invasive procedures, immunosuppression and cytotoxic chemotherapy, 
mortality has essentially remained unchanged at about 45%7 due to the lack of 
specific therapy aimed at the pathophysiology of sepsis.  
The primary trigger in the gram-negative septic shock syndrome is endotoxin, 
a constituent of the outer membrane of all gram-negative bacteria. Endotoxins consist 
of a polysaccharide portion and a lipid called lipid A, and are therefore also called 
lipopolysaccharides (LPS) (Figure 2).   
         Figure 1.  Incidence of Sepsis in the U.S. Data provided by Greg Martin.5,6 
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The polysaccharide portion consists of an O-antigen-specific polymer of 
repeating oligosaccharide units, the composition of which is highly varied among 
gram-negative bacteria. A relatively well-conserved core hetero-oligosaccharide 
covalently bridges the O-antigen-specific chain with the structurally highly conserved 
lipid A8;9. Lipid A is the active moiety of LPS10;11 and is composed of a hydrophilic, 
negatively charged bisphosphorylated diglucosamine backbone, and a hydrophobic 
domain of 6 (E. coli) or 7 (Salmonella) acyl chains in amide and ester linkages  
(Figure 2).12-14 
Whereas LPS itself is chemically inert, the presence of LPS in blood  
(endotoxemia), often a consequence of antibiotic therapy of preexisting bacterial 
infections, sets off a cascade of exaggerated host responses, which under normal, 
homeostatic conditions serve to orchestrate innate immune defenses. It is the 
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Figure 2. Schematic (left) and crystal structure (middle) of lipopolysaccharide (LPS). 
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uncontrolled, overwhelming, and precipitous systemic inflammatory response that 
ultimately manifests clinically in the frequently fatal shock syndrome characterized 
by endothelial damage, coagulopathy, loss of vascular tone, myocardial dysfunction, 
tissue hypoperfusion, and multiple-system organ failure.15 LPS activates almost every 
component of the cellular and humoral  (plasma protein) limbs of the immune system 
(Figure 3), resulting in the production of a plethora of proinflammatory mediators, 
important among which are the cytokines tumor necrosis factor α (TNF-α), 
interleukin 1β  (IL-1β), and IL-6, secreted mainly by monocytes and macrophages  
(Mφ).16 These cytokines and other mediators act in concert, amplifying the resultant 
generalized inflammatory processes. Endotoxemia and its deleterious sequelae may 
Figure 3. Schematic representation of immune activation by LPS 
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arise even in the absence of systemic gram-negative bacterial infections; conditions 
such as trauma17, burns18, and splanchnic ischemia during cardiac surgery19 or gram-
positive sepsis20 increase intestinal permeability, resulting in the spill-over into the 
portal circulation of LPS from the colon which is abundantly colonized by gram-
negative bacteria.  
Our understanding of basic mechanisms underlying the cellular response to 
LPS has increased vastly in recent years. Important research contributions include 
LPS recognition21 by CD1422-25  [and other cell surface recognition molecules]26;27 via 
an LPS-binding acute-phase plasma protein (LBP),28-30 initiation of signal 
transduction by toll-like receptor-431;32, and downstream cellular activation events 
mediated by mitogen-activated kinase p38 and c-Jun N-terminal kinase, leading to 
nuclear translocation of NF-κB33;34-36 resulting in cytokine mRNA transcription. 
These advances will likely offer novel therapeutic possibilities in the future.  
However, after more than two decades of intensive effort at evaluating more than 30 
investigational compounds, specific therapeutic options for sepsis have remained 
elusive. On June 29, 2000, Eli Lilly announced that favorable results had been 
obtained in Phase III clinical trials for Xigris™ (recombinant human activated protein 
C), an anticoagulant that targets a component of the humoral activation pathway and 
ameliorates disseminated intravascular coagulation. Clinical trials of recent years 
aimed at blocking various proinflammatory mediators including TNF-α, IL-1β, 
platelet-activating factor, and prostaglandins produced by the activated cellular 
components have all been disappointing37 (Figure 4), suggesting that targeting 
 18
downstream cellular inflammatory processes once immune activation has already 
progressed is unlikely to be of benefit.  
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Figure 4. Outcomes of clinical trials of anti-inflammatory agents in 
sepsis.  Adapted from Zeni et al., 1997 (Ref. 37). 
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1.2 Complexation of LPS by Macromolecules as a Therapeutic Strategy 
1.2.1 Polyclonal and Monoclonal Antibodies: As mentioned earlier, the 
polysaccharide portion of LPS is extremely variable and serologically distinct for 
each strain of the same species of gram-negative organisms. Although anti-O-
polysaccharide antibodies afford protection in experimental models where animals 
are challenged with homologous bacteria38, these are not likely to be of significant 
clinical value since sepsis runs an acute course before the pathogen is identified and 
appropriate specific immunotherapy is instituted. The biologically active part of LPS, 
lipid A, as well as the core oligosaccharide portion are structurally highly conserved 
across gram-negative genera, and thus are attractive targets for sequestration, and 
elimination of circulating LPS would, in principle, prevent the activation of 
inflammatory cascades. Experimental studies as early as 1968 suggested that 
antibodies directed toward epitopes in the core region of LPS may be broadly cross-
protective against a range of gram-negative organisms. However, neither human (HA-
1A)39 nor murine (E5)40 anti-lipid A monoclonal antibodies afforded significant 
protection in large, multiple, placebo-controlled clinical trials.7 In the wake of these 
failures, it became apparent that these monoclonal antibodies had been expedited 
through clinical trials without rigorous preclinical evaluation. Both HA-1A and E5 
exhibited low intrinsic binding affinities to LPS41 (<104 M-1), neutralized LPS poorly, 
bound promiscuously to a wide range of hydrophobic ligands such as lipoproteins and 
cardiolipin, as well as to a variety of human B cell and erythrocyte proteins,42 and 
proved to be toxic in a canine model of septic shock. Although the validity of 
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circulatory LPS as a therapeutic target is still viable, and efforts at developing core 
region-directed antibodies continue43,44 disappointing results obtained thus far could 
point to intrinsic problems with lipid antigens: poor immunogenicity, inaccessibility 
of neutralizing epitopes, the generation of nonspecific cross-reactive antibodies 
against irrelevant hydrophobic epitopes45, and potential problems with the antibody 
molecule itself: predominant intravascular compartmentalization, and possible tissue 
damage induced by activation of complement. Other immunotherapeutic strategies 
include the blockade of LPS binding to CD14 (the predominant cell-surface receptor 
for LPS) with anti-CD14 antibodies46;47 or anti-LBP antibodies.48 
1.2.2 Non-Antibody LPS-binding Proteins: The approach of neutralizing LPS or 
preventing cellular recognition by its cognate receptor (s) using non-antibody protein 
macromolecules is being actively pursued49, and notable developments in the area is 
bactericidal/permeability-increasing protein (BPI), a neutrophil azurophilic granule-
derived, antibacterial protein involved in innate host defense.50-52 On September 14, 
2000, Xoma Inc. announced favorable results of rBPI21 in preliminary clinical trials 
of severe pediatric meningococcemia, and has since obtained an FDA Subpart E 
designation for Phase III trials. Further ongoing trials will likely provide valuable 
data on the clinical efficacy of LPS neutralization by large, protein macromolecules 
of a size (23kDa) that would not efficiently cross endothelial barriers into interstitial 
spaces. 
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1.3 The paradigm of non-immunologic sequestration of LPS by small molecules 
1.3.1 Polymyxin B: The structurally invariant and biologically active center of LPS, 
lipid A, is a logical therapeutic target for neutralization. The anionic amphiphilic 
nature of lipid A enables it to interact with a variety of cationic hydrophobic 
ligands.53-55 Polymyxin B (PMB), a cationic amphiphilic cyclic decapeptide antibiotic 
isolated from Bacillus polymyxa56 has long been recognized to bind lipid A,57 and 
neutralize its toxicity in vitro and in animal models of endotoxemia.58-60 PMB has 
served as a "gold standard" for endotoxin-sequestering agents and is routinely used in 
experimental studies when a biological effect is to be verified as that due to LPS, or 
to abrogate activity of contaminating LPS. Listed in the US Pharmacopeia as a topical 
antibiotic, PMB is too toxic for parenteral use, which, while precluding its utility as 
an LPS-neutralizer in patients with sepsis, has stimulated the search for nontoxic 
PMB analogs61, PMB derivatives62-65 as well as other structurally diverse cationic 
amphiphilic peptides66-70, as candidate LPS-binding agents which are yet to be 
evaluated in clinical trials. A cartridge based on polymyxin B covalently immobilized 
via one of its NH2 groups to a polystyrene based fiber became available in Japan in 
late 2000 for clinical use (“Toraymyxin”, Toray Industries Inc., Tokyo).64 While this 
provides a clinically validated proof-of-principle for the value of sequestering 
circulating LPS, opportunities for extracorporeal hemoperfusion are rare: the typical 
patient is often profoundly hypotensive, with circulatory failure, refractory even to 
maximal vasopressor and intravenous fluid therapy regimens, underlining the need to 
develop alternate strategies for LPS sequestration.  
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The solution structure of PMB has been determined both in its free, aqueous,  
(Figure 5) as well as LPS-bound states.71;5  The cyclic moiety of aqueous PMB in its  
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Figure 5. Solution structure (top left), primary structure of Polymyxin B (PMB) (top 
right), NMR-derived conformation of the lipid A: PMB complex (bottom left) Arrows 
indicate salt-bridges. The methyloctanoyl acyl moiety attached to Dab1 is oriented 
normal to the plane of PMB. Bottom Right: Detail showing bidentate ionic H-bonds 
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unbound form is characterized by a type II' β-turn centered at D-Phe5, and a γ turn at 
Thr9 with no transannular H-bonds, features that are preserved also in the LPS-bound 
form. In the lipid A-PMB complex, (Figure 5) the carbonyl groups form a polar 
surface on one face of the cyclic portion which overlies the glycosidic hydrophilic 
backbone of lipid A, and the linear part, bearing the hydrocarbon chain, is parallel to 
the long axis of lipid A, and is apposed to the acyl chains of lipid A, the basis of the 
hydrophobic interaction of the peptide with LPS. The γ-NH2 groups of pairs of the 
Dab residues (Dab3/Dab4 and Dab7/Dab8) form bidentate ionic H-bonds with the lipid 
A phosphates (Figure 5).  
 
1.3.2 Structural correlates of affinity of LPS binding in nonpeptide small 
molecules: A number of classes of cationic amphiphilic drugs already in therapeutic 
use were screened for lipid A binding and LPS neutralization, among them 4-
aminoquinoline antimalarials, phenothiazine antipsychotics, biguanide 
hypoglycemics, the bis-diguanide antimicrobial, chlorhexidine, and the diamidine 
antiprotozoal, pentamidine. The criteria for selection of these classes was simply that 
these drugs were cationic amphiphiles.72 It was noted from these early, exploratory 
studies that dicationic bolaamphiphiles such as pentamidine and chlorhexidine bound 
lipid A strongly with apparent Kd values of 0.12 and 0.87 μM, respectively, the Kd for 
PMB, the reference compound being 0.37 μM  (Figure 6). The bisbiguandine, 
chlorhexidine, bound lipid A with an affinity about 80 times that of the 
monobiguanides, metformin and phenformin, and the Kd of pentamidine was greater 
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that of PMB (Figure 6). Both compounds antagonized LPS activity in the Limulus 
(horseshoe crab) amebocyte lysate gelation assay, an extremely sensitive in vitro test 
with a detection limit of 1 ng/mL of uncomplexed, bioactive LPS.72 This was the first 
indication that the presence of two basic groups separated by a distance could be a 
correlate of high binding affinity.  
 
 
1.4 Structural Correlates of LPS binding and Neutralization. 
1.4.1 Elucidation of the pharmacophore for lipid A binding: The amidinium  
(pentamidine) and guanidinium (chlorhexidine) groups are also strongly basic 
protonatable functions (see Figure 6) and it was therefore of interest to systematically 
examine the effect of varying inter-cationic distance and basicity  (pK) of the cationic 
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groups in model dicationic molecules.73 α, ω-Diaminoalkanes, the polyamines 
spermidine and spermine and their derivatives constituted a set of simple, linear 
molecules with inter-NH2 distances ranging between 5-16 Å (obtained by molecular 
modeling assuming extended conformations); N1- and N8-monoacetylated 
spermidine, and N4-benzylspermidine were used to test the importance of two 
cationic functions, and the possible role of bulky, hydrophobic nonterminal 
substituents, respectively. Comparisons of spermidine and N1, N8,-
diguanidospermidine (synthesized from spermidine using O-methylisourea) allowed 
the exploration of the hypothesis that basicity impacted upon augmented binding 
affinity. Pentamidine analogs shown in Figure 6 constituted another set of molecules 
with varying inter-cationic distance (Berenil: 12.82 Å - Pentamidine: 19.56 Å). The 
electron-donating methoxy group ortho to the amidinium function decreases its pK, 
and the imidazolino group is considerably less basic than the amidinium group 
(Figure 6). In brief, the findings were:  (a) The affinities of N1- or N8-monoacetylated 
spermidine were about 1/80th of spermidine, indicating that the presence of two 
cationic functions corresponded to enhanced affinity; (b) the affinity of 4-
benzylspermidine toward lipid A is about 2.4 times less than that of spermidine 
suggesting that nonterminal bulky "pendant" groups may sterically hinder 
complexation;  (c) a distinct sigmoidal relationship between intercationic distance and 
affinity toward lipid A was observed, with a sharp increase from 11Å, leveling off at 
about 13Å (Figure 7). This coincides, within experimental error, to the inter-
phosphate distance in energy-minimized models of lipid A, and in the crystal 
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structure of LPS  (13.9Å);  (d) pentamidine, and its methoxy- and imidazolino- 
analogs bound lipid A with identical affinity, as did spermidine and N1, N8-
diguanidospermidine, indicating that the pK of the terminal cationic function is not 
critical in determining binding affinity. However, the electrostatic interactions of 
cationic ligands with lipid A or LPS appear to mandatorily require the formation of 
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ionic H-bonds (salt-bridges) since several compounds with quaternized 
polyamidinium functionalities did not bind endotoxin  (data not shown). 
 The pseudo-bichromophoric nature of pentamidine  (see structure in Figure 6) 
ascribes unique photophysical properties, which were exploited in characterizing the 
mode of binding and nature of the drug-lipid A complex.73 Upon binding of 
pentamidine to lipid A [and not to other polyanions such as DNA74 that the drug is 
known to bind to], a unique emission band appears in the fluorescence spectrum 
which was ascertained to be due to inter-molecular excimer formation73, a 
consequence of the unique geometry and orientation of the chromophores in the 
pentamidine-lipid A complex. Under conditions when lipid A is completely 
monomeric  (in CHCl3/MeOH) pentamidine binds specifically to diphosphoryl, and 
not to monophosphoryl lipid A, with a 1:1 stoichiometry, indicating the bisamidine 
simultaneously recognizes the two anionic phosphates on the ends of the glycosidic 
backbone of lipid A73  (data not shown). The recognition of the phosphate group by 
the amidine is not sensitive to the specific orientation of the glycosidic 1-phosphate  
(which is thought to be an important determinant of biological activity of lipid A)8 
since both the α- and β-anomeric forms of phosphonooxyethyl analogs of synthetic 
lipid A [provided by S. Kusumoto75] are bound by pentamidine (data not shown). The 
interaction of the drug with the toxin is almost exclusively electrostatically driven, 
with negligible hydrophobic components, and is dependent on the ionization state of 
both the amidine and the phosphate, since protonation of either the lipid A phosphates 
(pH<5) or deprotonation of the amidinium groups of the drug (pH>10) results in 
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destabilization of the complex (data not shown). An energy-minimized model of the 
pentamidine: lipid A complex, derived from extensive biophysical characterization of 
the interactions is represented in Figure 8, showing the orientation of the drug with 
respect to lipid A, and the salt-bridges between the lipid A phosphate and the 
amidines. The model facilitates the consideration of possible sites of introducing 
sterically favorable hydrophobic groups that would be expected to enhance the 
entropic contributions of the free energies of interaction. 
  
Figure 8. Model of the pentamidine (van der Waals surface): 
bis-phosphoryl lipid-A complex (sticks). The P atoms of lipid 
A are space-filled. 
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1.4.2 Lipid A binding is necessary, but not sufficient for LPS neutralization: 
 That the recognition of LPS and subsequent binding by LPS-binding molecules does 
not necessarily result in inhibition of endotoxic activity can be adduced from the 
literature. For instance, LPS-binding protein  (LBP)28, an acute phase-reactant plasma 
protein synthesized by the liver under conditions of stress76, and the neutrophil 
granule-derived bactericidal/permeability increasing protein (BPI) are highly 
homologous in their sequences77;78 and bind LPS competitively79 with comparable 
affinities. Yet, whereas LBP "opsonizes" LPS80, and presents it to CD1481;82 initiating 
LPS-induced cellular activation processes83, the binding of BPI to LPS results in 
neutralization of endotoxic activity.84;85 Attempts at understanding the structural basis 
of this important functional difference led to the elucidation of high-resolution crystal 
structures of BPI86 and a Limulus (horseshoe crab) endotoxin binding protein 87 
[ENP].88;89 Another pertinent example is that of polymyxin B (PMB). It has been 
known for about a decade90 that polymyxin nonapeptide (PMN), with a single fatty 
acyl-Dab residue removed from its decapeptide parent molecule is virtually bereft of 
endotoxin-neutralization activity. PMB and PMN bind lipid A and LPS with identical 
affinities, and behave indistinguishably in a variety of spectroscopic assays designed 
to probe ligand-induced fluidity changes of the acyl domains of lipid A, bilayer-to-
nonlamellar phase transitions, and neutralization of the electrostatic double layer of 
lipid A or LPS aggregates.91 These data, taken together, point to the importance of 
stabilization of ligand-LPS complexes by hydrophobic interactions, a premise which 
has been examined for PMB using techniques such as surface plasmon resonance92 
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and titration calorimetry.93 The lack of comparison, however, for PMB and PMN in 
these studies92;93 has not yet permitted a complete and formal verification. 
 Pentamidine is an excellent case in point illustrating the binding is necessary, 
but not sufficient for neutralization. Whereas it binds LPS with an affinity even 
greater than that of PMB, only feeble inhibition of cytokine (Tumor Necrosis Factor-
alpha; TNF-α) release from LPS-stimulated human mononuclear cells was observed 
(Figure 9) and did not protect mice against lethal doses of LPS. 
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1.4.3 Structural correlates of neutralization of endotoxicity. The obligatory 
requirement of a hydrophobic moiety:  Having identified that the presence of two 
protonatable cationic groups positioned about 14 Å apart in a linear molecule was 
sufficient to ascribe high-affinity binding to LPS, and an additional hydrophobic 
moiety was necessary for the binding to result in neutralization of endotoxic activity  
(sequestration), experiments using the polyamines, spermidine (~ 11 Å; sub-optimal 
length), spermine (~16 Å, optimal length), and their monoacylated analogs94  (Figure 
10) were performed. Spermine was inactive while the acylated polyamines inhibited 
TNF-α release in a dose-dependent manner, the longer homologated spermine analog  
(Compound B) being more active than the monoacylated spermine analog [one 
terminal protonatable amine function is lost]  (Compound A, Figure 10) confirming 
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Figure 10. Structures of acylpolyamines (left), and inhibition of TNF-α 
induction in J774 cells stimulated with 25 ng/ml LPS (right). Essentially 
identical results were obtained with RAW cells. Similar inhibition profiles were 
obtained in nitric oxide (measured as nitrite) assays. 
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the necessity of optimal intercationic distance (see Figure 7). These results provided 
clear structural leads in efforts to recognize simple molecules that would behave as 
endotoxin sequestrants, and importantly, led to the identification of the 
pharmacophore for LPS-sequestration.  
 
1.5 Lipopolyamines as lead compounds for development of LPS sequestrants:  
The structural features that we had identified to be important in conferring 
LPS-sequestering properties are to be found in lipopolyamines, members of a 
burgeoning class of cationic lipid molecules designed to facilitate transfection of 
DNA into eukaryotic cells, now receiving increasing attention because of interest in 
human gene therapy.95-97 These molecules are of particular interest since they are 
designed to be of low toxicity to mammalian cells, and are being approved by the 
FDA for human use as safe alternatives to viral vectors.98-100 
Our proposal of evaluating lipopolyamines as potential endotoxin sequestering 
molecules was based on two simple heuristics which had been experimentally 
validated:  
Heuristic 1: An optimal distance of ~14 Å is necessary between protonatable 
functions in bis-cationic molecules for simultaneous ionic interactions with the 
glycosidic phosphates on lipid A, it is the bis-cationic scaffold that is the principal 
determinant of binding affinity (Figure 7).101;102  
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Heuristic 2: Binding is necessary, but not sufficient for activity, and an additional, 
appropriately positioned hydrophobic group is obligatory for the interaction to 
manifest in neutralization of endotoxicity.103;104 
 For the sake of brevity, salient aspects of key structure-activity relationships 
in one homologous series of twelve mono- and bis-acyl homologated spermine 
analogs (Figure 11) will be first discussed.105 
 
 
 
 
 
 
 
Two questions were addressed in this study: (i) what is the optimal hydrophobic chain 
length for effective anti-endotoxic activity, (ii) are symmetrical bis-acyl spermines 
more effective than mono-acyl compounds. It was found that a carbon number of 14-
16 was optimal in mono-acyl spermines (Figure 12) which were in general, as potent 
as their bis-homologs and, in addition, showed lower surface activity (lower 
nonspecific cytotoxicity). 
In comparing the NO and TNF-α inhibition profiles with the LPS-binding 
affinities for this congeneric series, with the exception of 1a, all of the other mono-
acyl compounds bound LPS with ED50 values between ~1-2 μM, while only the 
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longer acyl chain compounds (1d-f) were biologically active (Figure 12). This result 
emphasized the necessity of employing a biological primary screen in tandem with 
the displacement assay in order to derive reliable structure-activity relationships in 
LPS-sequestering compounds. The apparent inverse correlation between ED50 and 
neutralization potency for the bis-acyl 2 series was simply a consequence of the poor 
solubility of these homologues. Free aqueous concentrations of the bis-acyl 
compounds were progressively retarded with increasing chain length, diminishing 
binding and, consequently, neutralization (Figure 12). The protective effects of 1e 
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Figure 12. Correlation between carbon number of the hydrocarbon group in 
mono- (open stars, dotted line) and bis-acyl (closed stars, solid line) and TNF-α 
inhibition in human blood (top) and NO inhibition in murine J774A.1 cells 
(bottom). Data represent means of duplicate values obtained from a 
representative experiment. 
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(the most potent compound in the human TNF-α inhibition assay), 2a (most active in 
inhibiting NO release in J774A.1 cells), and 2c (which was of lower potency than 
either 1e or 2a in both assays) were characterized in a murine model of endotoxemic 
sepsis. A supralethal dose (2X the dose causing 100% lethality) of 200 ng/mouse was 
administered intraperitoneally (i.p.) and separate i.p. injections of graded doses of 
compound, and lethality was observed at 24 h. As is evident from Table 1, a clear 
dose-response was observed, with 1e affording complete protection at the 100 or 200 
μg/mouse dose, and partial protection at the 50 μg dose. Both the bis-compounds 
were found to be inferior to 1e, suggesting that in vitro inhibition of TNF-α was 
correlated better with outcomes in in vivo animal models of sepsis. 
 
 
 
Compound  Compound Dose 
(µg / mouse) 1e 2a 2c 
200 0/5* 1/5* 1/5* 
100 0/5* 4/5 2/5 
50 2/5 5/5 4/5 
10 5/5 5/5 4/5 
0 5/5 5/5 5/5 
 
 
Table 1. Dose-dependent protection of CF-1 mice challenged with a supralethal dose of 
200 ng/mouse (LD100 = 100 ng) by the acylhomospermines in cohorts of five animals. 
Lethality was recorded at 24 h post-challenge. Ratios denote dead/total. Asterixes 
indicate statistically significant values, p<0.05. 
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Chapter 2 
 
Synthesis and Evaluation Of Amide Analogues Of a Bis-Holomologated,  
Bis-Alkyl Spermine Compound  
2.1 Background 
Both the terminal amines of the bis-homologated, bis-acyl 2 series are acylated 
(Figure 11), and therefore non-protonatable, which could potentially account for the 
poorer activity of the 2 series as shown in Figure 12. Furthermore, molecular 
modeling studies suggested that both the internal as well as the external amines could 
participate in ionic H-bonds with the glycosidic phosphate groups, as well as the 
carboxylates of the 3-deoxy-D-manno-octulosonic acid (KDO) residues of the core 
glycolipid portion of LPS (Figure 13). We therefore wished to examine the relative 
importance of the potential salt bridges, and decided to investigate this by 
synthesizing analogues of 2e, with the internal and external amines replaced by 
amides. 
 
N N
N N
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N N
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H H
C 14H 29C 14H 29
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Figure 13.  Left: Molecular model of a bis-homologated, bis-alkyl polyamine 
docked on LPS, showing bidentate ionic H-bonds with the lipid A phosphate 
groups and the external amines, as well as the carboxylates of the KDO sugars of 
the core-glycolipid, with the internal amines. Right: Structure of 2e with terminal 
bis-acyl groups, and possible sites for introducing amide functionalities. 
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2.2 Synthesis of internal bis-amide analogue, 7 (Scheme 1) 
The targeted bis-amide 7 was prepared from the commercially available β-alanine 
methyl ester 3 to which acrylonitrile was Michael-added in the presence of 
triethylamine, followed by addition of a solution of di-tert-butyl dicarbonate in 
methanol to give a colorless oil 4. The solution of the mono-nitrile 4 and 
hexadecylamine in methanol was reductively monoalkylated106 using Pd(OH)2/C 
under 60 psi hydrogenation conditions to yield the secondary amine 5. This was 
followed by the addition of a solution of di-tert-butyl dicarbonate in the presence of 
triethylamine to afford 6 as viscous oil. The ester 6 was hydrolyzed with LiOH in 
water to afford the acid, which was thereafter coupled with 1, 4-diaminobutane using 
DCC, resulting in the Boc-protected precursor of the product. This precursor was 
deprotected using dry trifluoroacetic acid to provide the bis-C16 alkylated, bis-
homologated spermine analogue 7 as the trifluoroacetate salt.  
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2.3 Synthesis of external bis-amide analogue, 11 (Scheme 2) 
Compound 11 was obtained by N-alkylation of β-alanine methyl ester 3 with 1-
bromohexadecane in the presence of triethylamine, to afford 8. The resulting 
secondary amine was Boc-protected by the addition of a solution of di-tert-butyl 
dicarbonate to give colorless oil 9. The ester 9 was hydrolyzed with LiOH in water to 
afford the acid which was thereafter coupled with di-Boc spermine 20 (synthesis as 
reported earlier107) using DCC in the presence of catalytic amounts of DMAP to 
afford the Boc-protected coupled product 10. This final precursor was deprotected 
with dry trifluoroacetic acid resulting in the bis-C16 alkylated bis-homologated 
spermine analogue with external amides 11 as the tetratrifluoroacetate salt.  
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2.4 LPS-binding affinity of the internal and external amide analogues. 
 
 
 
The binding affinities of the bis-amide compounds to LPS were first examined 
quantitatively using a rapid and robust high-throughput fluorescence displacement 
assay described previously.108 The assay, in its entirety, consists of three automated 
steps: (i) in-plate serial dilution of compounds; (ii) addition of a mixture of LPS and 
BODPIY-cadaverine; and (iii) recording end-point fluorescence intensity at a fixed 
wavelength (620nm) in a plate reader. The addition of test compounds results in de-
quenching of LPS-bound BC fluorescence, manifesting in emission intensity 
enhancements. The apparent binding affinities of the compounds, computed from 
displacement curves shown in Figure 14, are: 11.4 μM (7), 2.2 μM (11), and 0.45 
μM (Polymyxin B). Although the binding affinities of both these analogues are quite 
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Figure 14.  Determination of binding affinity of the bis-amide compounds using a 
reported BODIPY-cadaverine/LPS displacement assay. Polymyxin B was used as 
a reference compound. 
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poor compared to Polymyxin B, the affinity toward LPS of Compound 11 is 
substantially better than that of 7, suggesting the involvement of the internal amines 
in possible ionic H-bonds with the KDO-carboxylates of the inner core region, as 
mentioned above. 
 
2.5 LPS-neutralization potency in vitro of the internal and external amide 
analogues Next, we tested the in vitro biological activity in terms of their LPS-
neutralization potency in a reporter gene assay. The inhibition of induction of NF-κB 
is a key transcriptional activator of the innate immune system, leading to uncontrolled 
cytokine release which ultimately leads to multiple organ failure and the shock 
syndrome. The nuclear translocation of NF-κB by LPS is attenuated in a dose-
dependent manner when free LPS is bound (and sequestered) by LPS-sequestering 
compounds, allowing the potency of LPS neutralization to be measured directly aIC50 
values. NF-κB nuclear translocation was quantified using human embryonic kidney 
293 cells cotransfected with TLR4 (LPS receptor), CD14 and MD2 (co-receptors), 
available from InvivoGen, Inc., (HEK-Blue™, San Diego, CA) as per protocols  
provided by the vendor. Stable expression of secreted alkaline phosphatase (seAP) 
under the control of NF-κB/AP-1 promoters is inducible by LPS, and extracellular 
seAP in the supernatant is proportional to NF-kB induction. seAP was assayed 
spectrophotometrically using an alkaline phosphatase-specific chromogen at 620 nm 
using a rapid-throughput, automated protocol employing a Bio-Tek P2000  liquid 
handler. 
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It was found, however, that both the bis-amide compounds inhibited LPS-induced 
NF-κB activation very poorly (Figure 15). Ongoing structure-activity studies had 
indicated that mono-acyl,107-109 or mono-alkyl110 compounds, rather that analogues 
substituted on both ends, were found to be very active. Our attention, therefore, 
turned to the synthesis and detailed evaluation of a mono-C16-alkyl-homospermine 
compound as described in the following chapter. 
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Figure 15. Concentration-dependent inhibition of nuclear translocation of NF-κB in 
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Chapter 3 
 
Synthesis And Biological Evaluation Of a Novel, N-Alkyl Homospermine LPS 
Sequestrant 
 
 
3.1 Design rationale for the N-alkyl homospermine compound: 
It was hypothesized that the presence of multiple, protonated secondary amines (H-
bond donors and positive charge) would provide for optimal salt-bridges with the 
lipid A phosphates and the KDO carboxylate groups since data on the analogue with 
internal amides (7) pointed to the importance of incorporating such functional groups. 
Iterative cycles of pharmacophore-based ligand design led us to consider mono-
functionalized derivatives, since bis-acyl or bis-alkyl compounds were found to be 
weak LPS-neutralizers, presumably a consequence of very poor aqueous solubility. It 
was therefore logical to synthesize and evaluate a mono-alkyl homospermine 
analogue. 
 
3.2 Synthesis of the N-alkyl homospermine compound (17): 
 
The tri-Boc-Spermine 14 was synthesized from spermine 12 as per a procedure 
reported previously.107 To this intermediate 14, as shown in Scheme 3, Michael 
addition with acrylonitrile, followed by protection of the amine was carried out by the 
addition of di-tert-butyl dicarbonate in methanol to afford the mono-nitrile derivative 
15. The nitrile 15 was reductively monoalkylated106 with hexadecylamine in methanol 
using Pd(OH)2/C to give the secondary amine which was Boc-protected with di-tert-
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butyl dicarbonate in the presence of triethylamine to afford 16 as a viscous oil. This 
precursor was finally deprotected with dry trifluoroacetic acid to give the mono 
homologated mono C16 alkyl spermine as the penta-trifluoroacetate salt, 17.  
 
3.3 Large-scale synthesis of the N-alkyl homospermine compound (17): 
The starting material (spermine) used in Scheme 3 is prohibitively expensive, and 
multi-gram quantities of 17 became necessary for detailed in vivo evaluation of 
pharmacodynamic, pharmacokinetic, and toxicological studies. 1, 4-diaminobutane 
18 (putrescine) which is inexpensive, was used as the staring material for these 
purposes. As shown in Scheme 4, to the compound 18 acrylonitrile was added, 
followed by the addition of solution of di-tert-butyl dicarbonate in methanol to give 
the bis-nitrile derivative 19, which was reduced with Pd(OH)2/C in glacial acetic acid 
to afford di-Boc-spermine107 20. To hexadecylamine 21, acrylonitrile was added, 
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followed by the addition of solution of di-tert-butyl dicarbonate in methanol to give 
the N-Boc-mono-nitrile derivative 22. Compound 20 and 22 were then coupled by 
reductive monoalkylation using Pd(OH)2/C under 60 psi hydrogenation conditions to 
provide the secondary amine 23. It is to be noted that under these conditions, both the 
mono-and bis-substituted compounds can, and indeed, did form. Reductive 
monoalkylation of 22 with excess of di-Boc-spermine, followed by isolation of the 
mono-substituted precursor afforded 23 in good amounts. This precursor was 
deprotected with dry trifluoroacetic acid to give the desired product 17 as the 
trifluoroacetate salt.  
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3.4 Binding affinity and in vitro neutralization activity.  The binding affinities of 
17 and PMB to LPS were determined using the BODIPY®-TR-cadaverine (BC) 
assay mentioned earlier.108 The effective probe displacement (ED50) values for 17 and 
PMB were found to be virtually identical: 1.2 + 0.16 μM, and 1.31 + 0.12 μM, 
respectively (Figure 16A).  
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Figure 16. (A) Binding affinity of 17 and PMB (reference) to LPS determined by 
BODIPY-cadaverine displacement assay. The ED50 values for the two compounds are 
1.2 + 0.16 μM, and 1.31+0.12 μM, respectively. (B) Inhibitory activity of 17 and PMB 
in LPS-stimulated murine J774 macrophage cells. The IC50 values for 17 and PMB 
are, respectively, 21+3 nM and 27+2 nM. 
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Murine, but not human monocytes, produce measurable quantities of nitric 
oxide (NO), an important surrogate marker of immune activation by bacterial 
products.111  Compound 17 as well as PMB inhibited NO production in a 
concentration-dependent manner in murine J774A.1 cells stimulated with 10 ng/ml 
LPS, the IC50 values for 17 and PMB being 21 + 3 nM and 27 + 2 nM respectively 
(Figure 16B). 
Similarly, 17 and PMB inhibited LPS-induced NF-κB induction with virtually 
indistinguishable IC50 values (32 + 2 nM), but showed no effect of TNF α-stimulated 
cells (Fig. 17).  
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Figure 17. Inhibition of NF-κB reporter gene induction in HEK-293 cells 
stably transfected with Tlr-4/CD-14/MD-2/NF-κB-sAP construct. Cells 
were either stimulated with LPS (10 ng/ml) or recombinant human TNF-α 
(100 ng/ml), and exposed to graded concentrations of test compounds. 
Both 17 and PMB inhibit LPS-stimulated NF-κB induction with identical 
potency (IC50: 32 + 2 nM), but show no effect of TNF-α-stimulated cells, 
showing specificity of action. Shown on the left are negative and positive 
(LPS alone and TNFα alone) controls
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  Specificity of action for both PMB and 17 could also be demonstrated by 
showing that the IC50 values were inversely related to the stimulus (LPS) 
concentration in a Schild-type plot (Figure 18A). Non-covalent ligands are expected 
to obey the Law of Mass Action. Consequently, higher concentrations of LPS need 
correspondingly higher doses of LPS-binding ligands to neutralize the activity. 
Mention was already made that 17 showed no effect of TNF-α-stimulated cells 
(Figure 17), indicating that the compound, like polymyxin B, specifically sequesters 
LPS and inhibits its toxicity. 
 
An ideal LPS sequestrant of potential clinical utility should be one which 
binds to and neutralizes a wide range of endotoxins from different Gram-negative 
bacteria. Although the lipid A portion of LPS is structurally highly conserved 112, 
substoichiometric substitutions on the phosphate group with aminoarabinose or 
phosphoethanolamine 113 as seen, for example, in S. enterica var. typhimurium, can 
significantly alter the binding of cationic antimicrobials such as PMB.114 We 
therefore examined if 17 would effectively neutralize a broad range of LPS (E. coli 
0111:B4, E. coli 055:B5, S. abortus equi, P. aeruginosa, and V. cholera) in the NF-
κB assay. We found that this was indeed the case (Figure 3C), with the IC50 values 
being very similar for most LPS species (~ 30 nM). Interestingly, we also observed 
that 17 was approximately eight-fold more potent than PMB in inhibiting S. abortus 
LPS (Figure 18B).  
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3.5 Ex vivo neutralization activity in human blood: 
We sought to verify that the endotoxin-sequestering activity of 17 would be 
manifested in the milieu of whole human blood, characterized not only by its high 
ionic strength (~300 mOsmoles) which attenuates electrostatic interactions,102 but 
also by near-millimolar concentrations of albumin. Albumin has been shown to bind 
LPS.115 Also present in human serum are a number of high-affinity LPS-binding 
proteins such as soluble CD-14116 and LPS-binding protein.117 Furthermore, given the 
amphipathic nature of both LPS and 17, it is conceivable that substantial partitioning 
of both target and ligand into the lipoprotein constituents could occur as has been 
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Figure 18. (A) Schild-type analysis of dependence of IC50 (NF-κB induction) 
of 17 and PMB on the dose of LPS used. (B) Inhibition of NF-κB reporter 
gene induction by 17 and PMB in HEK-293 cells stimulated with 10 ng/ml 
LPS isolated from a wide variety of Gram-negative bacteria. 
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observed with E5564, a lipid A receptor antagonist currently undergoing clinical 
trials.118 For these reasons, and prior to initiating in vivo evaluation, we compared the 
effects of 17 and PMB in two ex vivo assays using whole human blood.  
 In the first, we examined the specificity and potency of 17 relative to PMB in 
inhibiting the phosphorylation of p38 mitogen activated protein kinase (p38MAPK), a 
key component of a phosphorylation cascade that is upstream of NF-κB.119  Exposure 
of whole blood obtained from healthy human volunteers to 100 ng/ml LPS results in a 
marked elevation in T180/Y182 dual-phosphorylated p38MAPK as probed by flow 
cytometry using a phycoerythrin (PE)-labeled anti-phospho-p38 MAPK (T180/Y182) 
antibody (Figure 19A). The activation seems to occur chiefly in polymorphonuclear 
(PMN) cells since the positive population maps directly to the subset of cells 
adjudged as PMN based on forward and side-scatter characteristics. The addition of 
either PMB or 17 concomitant with LPS exposure results in a concentration-
dependent attenuation of p38MAPK phosphorylation with the potencies of both 
compounds being very similar. Notably, p38MAPK phosphorylation induced by 
TNF-α is affected by neither compound, emphasizing again the specificity of action 
against LPS (Figure 19A). 
 We next evaluated the efficacy of 17 in inhibiting proinflammatory cytokine 
release in whole human blood, using a multiplexed cytokine detection system.105 
Compound 17 inhibits TNF-α, IL-6 and IL-8 production, with the IC50 of 3-5 μM (an 
LPS stimulus of 100 ng/ml was used), which is considerably lower than that of PMB 
(11-13 μM) (Figure 19 C, D, E).  
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Figure 19. (A) Inhibition of p38 MAP kinase phosphorylation in whole human blood (ex 
vivo), stimulated with either LPS (100ng/ml) or hTNF-α (100 ng/ml) for 15 minutes with 
graded concentrations of 17 or PMB. Quantification of p38 MAPK was performed using flow 
cytometry. (B) Back-gating on the p38 MAPK-positive cells (red-shaded peak) map to the 
polymorphonuclear population in the forward scatter/side scatter profile. (C) Inhibition of 
LPS-induced proinflammatory cytokine production in human blood stimulated with 100 
ng/ml LPS pre-incubated with graded concentrations of either 17 or PMB. Cytokine levels 
were quantified using a multiplexed flow-cytometric bead array system (CBA). 
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3.6 Efficacy in murine models of septic shock. A well-established murine model of 
lethal septic shock105;120;121 was employed to compare the potencies of 17 with PMB. 
Cohorts of 10 CF-1 mice per group, sensitized to the lethal effects of LPS with D-
galactosamine, were challenged with a supralethal dose of LPS (2X LD100 dose = 200 
ng/animal) administered intraperitoneally (i.p.). This was preceded by a subcutaneous 
(s.c.) injection of graded doses of test compounds given one hour prior to LPS 
challenge. Although a similar pattern of dose-dependent increase in survival was 
observed for both compounds, 17 afforded significantly better protection than PMB at 
4 mg/kg (p<0.01; χ2 test) (Fig. 5A). It was confirmed that the protection afforded by 
17 was attributable to attenuated LPS-induced cytokine production (Figure 20). It 
was also of interest to characterize the pharmacodynamics of 17 in time-course 
experiments in order to estimate the duration of action of 17.  Mice were administered 
17 at a dose of 8 mg/kg s.c. at various time points before and after a supralethal LPS 
challenge. As depicted in Figure 20, 17 was maximally effective when it was 
administered concurrent to LPS administration; the data further suggested that 
sufficiently high plasma concentrations apparently persisted even up to 8 h so as to 
provide partial protection against LPS-induced lethality (Figure 20). It is to be noted 
that 17 was bereft of any protective effect if administered following LPS challenge, 
suggesting that once the innate immune system has responded to the presence of 
circulatory LPS, anti-endotoxin agents are unlikely to be of any benefit, and thus can 
only be used as prophylactic agents to prevent the onset of septic shock. 
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3.7 Pharmacokinetics of 17 in rodents: 
As shown in Figure 20A, time-course pharmacodynamic experiments indicated 
partial protection when 17 was administered 12 h prior to LPS challenge suggesting 
that the compound was fairly long-lived in systemic circulation.122 Three questions 
were of interest: (a) what is the elimination half-life of 17 in the murine model, and 
does the t½ correspond to pharmacodynamic data; (b) what is the therapeutic plasma 
concentration of 17 that corresponds to full protection against endotoxemic challenge 
in mice; and (iii) are there significant interspecies differences in pharmacokinetic 
parameters of 17 in rodents. A dose of 200 μg/animal (8 mg/kg) of 17 was 
administered to CF1 mice via intraperitoneal and intravenous routes. Plasma 
concentrations of 17 were determined by LC-MS/MS using a deuterated 17 internal 
standard, synthesized in Prof. Dutta’s laboratory, the synthesis of which will therefore 
not be presented herein (Figure 21). The alkylpolyamine 17 appears to be a low-
clearance compound with quite a long elimination t½ of about 6.5 - 7 h. The strong 
binding of DS-96 to albumin (data not shown) may be contributory to its persistence 
in systemic circulation. Importantly, the PK data are consistent with the time-course 
pharmacodynamics experiments (Figure 20), wherein partial protection was observed 
at -4 h w.r.t. LPS challenge. Taken together with the observed Cmax values in the 
murine I.P. model (Figure 21), a therapeutic plasma concentration of ~1 μg/ml of 17 
is therapeutic, and corresponds to full protection against LPS. 
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3.8 Summary: 
The synthesis and detailed characterization of 17, a novel mono-alkylated 
homospermine derivative, designed from first principles to specifically recognize and 
bind to the structurally conserved lipid A moiety of LPS, has been undertaken. The 
mode of binding  appears to involve the simultaneous interactions of the terminal 
amines of 17 with the bis-phosphorylated diglucosamine backbone of lipid A, while 
the C16-alkyl functionality is thought to additionally stabilize the complex via 
interactions with the polyacyl hydrophobic domain of lipid A.123 The interaction of 17 
with LPS resulted not only in an inhibition of proximal LPS-induced cell-signaling 
events, but also of downstream proinflammatory cytokine production in human blood. 
The potency of 17 rivaled that of PMB and, in some key assays, including a murine 
model of endotoxic shock, was superior to PMB. Consistent with the in vitro 
sequestration activity of the alkylpolyamine compound, a dose-dependent protection 
by 17 against LPS-induced lethality was observed in a well-characterized murine 
model. The time-course of protection suggested that the compound was long-lived 
since partial protection was observed when it was administered up to 12 h preceding 
LPS challenge.124  
As an LPS sequestrant, therapeutic concentrations must be present before the 
onset of endotoxemia as was shown by time-course pharmacodynamic experiments. 
Its utility will therefore be as a prophylactic, perhaps as an adjunct with conventional 
antimicrobial chemotherapy. Its long elimination t½ suggests that the compound may 
be given hours before the onset of sepsis. 
 56
Chapter 4 
Further SAR on N-alkylpolyamines. Exploration of spermidine/spermine and 
norspermidine/norspermine backbones. 
4.1 Background and Rationale: 
Several iterative design-and-test cycles of SAR studies, including high-throughput 
screens73;109;110;125-131 had converged on the polyamine scaffold which was extensively 
investigated with particular reference to the number, position, and length of acyl or 
alkyl appendages. Our investigations thus far focused on homologated spermine 
scaffolds and decorated with one or more acyl or alkyl group on the ends of the 
backbone. Figure 22 shows a representative SAR analyses.110  
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Dose-response profiles had indicated a clear segregation of activity based on 
structural class, with the potencies of bis-substituted compounds worse than mono-
substituted analogues. Importantly, this SAR led to the identification of 17 as an 
exciting lead with an IC50 value of 37 nM, which is indistinguishable from that of 
polymyxin B, the ‘gold standard’ for LPS sequestrants. However, the polyamine 
backbone [spermine: NH2-(CH2)3-NH-(CH2)4-NH-(CH2)3-NH2], itself, had not been 
explored sufficiently, and it was not known if incremental variations on the 
polymethylene spacing would affect LPS-binding and neutralization properties. 
Furthermore, the original hypothesis pertaining to the NH2←--→NH2 pharmacophore 
allowing for simultaneous interactions with the lipid A phosphate groups/KDO 
carboxylates was empirical, and only the effect of acyl and/or alkyl chain lengths had 
been examined. Two recent crystal structures of LPS indicate that the distance 
between the P atoms in the phosphate groups of lipid A is 12.45 Å (Figure 23) 132;133. 
The Cartesian distance between the centroids of the charge-delocalized electron cloud 
of the PO42- ↔PO42- is computed to about 14.5 Å. It is to be noted that this vector is 
merely a mathematical construct since it may transect atoms, and a realistic distance 
may be slightly longer. It was of interest to experimentally test this hypothesis in a 
congeneric series of compounds wherein only the length of the polyamine backbone, 
and not the hydrophobic appendage, was systematically varied. For these reasons, it 
was decided to systematically explore the relationship between variously elongated 
spermidine [NH2-(CH2)3-NH-(CH2)4-NH2] and norspermidine [NH2-(CH2)3-NH-
(CH2)3-NH2] backbones, with the N-alkyl group being held constant at C16. We 
14Å 
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elected to examine these two sets of analogues which vary one from the other by only 
one methylene unit (Figure 24) in order to examine if changing the spacing between 
the inner secondary amines may yield additional SAR information. 
Figure 23. Interphosphate distance in a crystal structure of LPS. 
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4.2 Correlation of backbone length and activity in norspermidine/spermidine-
type analogues: 
The activities of these two sets of compounds were first evaluated in the primary in 
vitro biological screen employing the inhibition of LPS-induced nitric oxide (NO) 
production in murine J774 cells. As seen in Fig. 25, there is a progressive increase in 
the potency of the compounds with increasing length of the backbone, with an 
inflection point around 15 Å, which correlates well with the expected inter-phosphate 
distance. Further elongation of the backbone does not result in a commensurate 
increase in activity. 
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4.3 Differential activities of the spermine and norspermine compounds in the 
inhibition of LPS-induced NF-κB translocation. 
The NO inhibition assay (Figure 25) was used as a preliminary biological screen to 
evaluate the activities of these compounds. The NF-κB assay described previously 
(Section 2.5, Figure 15) is more sensitive, has a wider dynamic range, and has much 
lower coefficients of variation (<3%). It was therefore used to confirm the NO 
inhibition data and to probe whether fine differences between these two sets of 
compounds existed. As shown in Figure 26, a similar inflection point in the IC50 
values were observed; however, the norspermine-type compounds consistently 
showed higher activity compared to the spermine homologues. Specifically, the 
longest 3-3-3-3-3 compound 53 exhibited higher potency that the 3-3-4-3-3 bis-
homologated spermine analogue, 33, as was also the case for the mono-homologated 
pair 17 and 48, and the norspermine/spermine compounds, 29 and 41 (Figure 26). 
These data suggest that the propylene spacing of the norspermine series allows for 
better interactions with LPS. Somewhat unexpectedly, it was found that increasing 
the backbone length did not result in a ‘saturation’ in the activity profile, but led to 
incremental enhancements of LPS-neutralizing activity even at about 25 Å. At first 
sight this may seem to be incongruent with the original hypothesis of an optimal 
distance of ~15 Å, but it is to be noted that these higher homologues have also 
increased aqueous solubility (and lower binding to human serum albumin) due to the 
presence of additional amino groups. It is possible, therefore, that the introduction of 
highly polar functional groups on the molecule that would substantially increase 
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water solubility may result in more potent analogues. Such functional groups may be, 
for instance, hydroxyls. Anionic groups such as phosphates or sulfonates would 
render the molecule zwitterionic and may also hinder ionic interactions with the 
internal KDO carboxylates on the core glycolipid. These hypotheses remain to be 
tested. 
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Figure 26. Correlation of inter-nitrogen distance in 
spermine/norspermine compounds and LPS-sequestering activity in 
the NF-κB translocation assay. 
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4.4 Summary and conclusions. 
Simple cationic amphipathic molecules possessing the key structural properties of  (a) 
bis-cationicity,  (b) protonatable cationic functions separated by a distance of about 
15 Å, and  (c), a hydrophobic substituent placed such that steric interference is 
minimized possess LPS-binding and –neutralizing properties. The alkylpolyamines 
exemplify this class of molecules. In our continuing efforts to refine our 
understanding of the structure-activity relationships in such molecules, we have 
recently identified a novel N1-alkyl-monohomologated spermine derivative (17), and 
shown that it binds LPS and neutralizes its toxicity, affording complete protection in a 
murine model of LPS-induced lethality. Examination of a series of compounds in 
which the backbone   length was systematically varied provided a confirmation of the 
hypothesis pertaining to the pharmacophore for binding and neutralizing LPS. 
Significant benefits of therapeutic approaches targeting LPS itself is that potentially 
advantageous components of host defense mechanisms are not compromised and an 
anti-endotoxin agent of low toxicity can be used prophylactically in patient subsets 
predisposed to developing sepsis, which will not be feasible with anti-inflammatory 
agents or other interventions that target distal, downstream pathogenetic processes. 
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Chapter 5 
Experimental Data 
5.1 Materials and Methods 
 
Proton and carbon nuclear magnetic resonance spectra were recorded using a Bruker 
DRX 400 MHz or Bruker DRX 500 MHz spectrometer. All chemical shifts were 
recorded (δ) as parts per million (ppm), and all the samples were dissolved in CDCl3 
using residual solvent as internal standard unless otherwise noted. Mass spectra were 
obtained from Agilent ESI-TOF mass spectrometer at a mass accuracy of 20 ppm. All 
moisture-sensitive reactions were performed using either oven or flame dried 
glassware (120oC) under a positive pressure of argon unless otherwise noted. Solvents 
and reagents that are commercially available were used without further purification 
unless otherwise noted. All silica gel 635 (60-100 mesh) used for column 
chromatography was purchased from Sigma-Aldrich, Inc. while thin layer 
chromatography were performed using silica gel CCM pre-coated aluminum sheets, 
purchased from Sorbent Technologies, Inc. All compounds were concentrated and 
dried using standard rotary evaporator and high vacuum techniques.  
 
5.2 Experimental Procedures: 
5.2.1 Synthesis of Internal amide Bis-C16-alkylhomospermine and External 
 amide Bis-C16-alkylhomospermine 
 
 MeO N
O
Boc
CN
4
 66
Conversion of 3 to 4.  To a solution of ß-alanine methyl ester 3 (0.5 g, 4.85 mmol) in 
methanol (10 mL) at room temperature was added triethylamine (0.7 mL, 4.85 mmol) 
followed by acrylonitrile (0.32 mL, 4.85 mmol). The mixture was stirred at room 
temperature for 15 h. After removal of solvent under high vaccum, the nitrile 
derivative was dissolved in 30 ml of DCM followed by addition of solution of di-tert-
butyl dicarbonate (5.2 g, 24.2 mmol) in DCM (15 mL). The resulting solution was 
stirred for 12 h at room temperature, concentrated in vaccum, and purified by flash 
column chromatography (EtOAc: Hexane = 15 : 85) to give a colorless oil 4 (.9 g, 72 
%) 1H NMR (400 MHz, CDCl3) δ 1.5 (s, 9H), 2.67 (t, 4H), 3.2 (m, 4H), 3.6 (s, 3H); 
13C NMR (100.6 MHz, CDCl3); 17.01, 28.3, 33.4, 44.6, 51.8, 79.4, 118.3, 154.9, 
172.5; MS(ESI) calculated for C12H20N2O4 m/z 256.14 found 279.13(MNa)+. 
 
 
 
Conversion of 4 to 5. A solution of mono-nitrile 4 (0.5 g, 1.95 mmol) and 
hexadecylamine (2.35 g, 9.75 mmol) in methanol (20 mL) was hydrogenated over 
Pd(OH)2/C (0.1 g) at 60 psi pressure for 12 h at room temperature. The catalyst was 
removed by filtration and the residue was washed thoroughly with methanol. After 
removal of solvent under high vaccum, the crude secondary amine alkylated 
compound (0.41 g, 0.85 mmol, 43%) was dissolved in methanol (30 ml) followed by 
the addition of di-tert-butyl dicarbonate (2.12 g, 9.75 mmol) in a solution of methanol 
(15 ml). The resulting solution was stirred for 12 h at ambient temperature, 
MeO N
O
Boc
N
C16H33
5
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concentrated in vaccum and purified by flash column chromatography (EtOAc: 
Hexane = 10 : 90 to 12 : 88 ) to give compound 5 (.49 g, 43 %) as a viscous oil. 1H 
NMR (400 MHz, CDCl3) δ 0.86 (t, J =11.7, 3H), 1.26–1.29 (s, 26H), 1.42-1.52 (br s, 
20 H), 1.81 (br m, 2H), 2.6 (t, 2H), 3.1 (t, 6H), 3.3 (t, 2H), 3.5 (s, 3H); 13C NMR 
(100.6 MHz, CDCl3); 14.1, 22.7, 24.6, 27.5, 28.4, 29.6, 31.8, 33.7, 43.6, 44.7, 45.8, 
46.3, 47.0, 48.6, 51.8, 79.8, 149, 156.4, 174.2; MS(ESI) calculated for C33H64N2O6 
m/z 584.5 found 607.4 (MNa)+. 
 
 
 
Conversion of 5 to 6. To a stirred solution of mono-alkylated methyl ester 5 (0.45 g, 
.77 mmol) in THF (10 mL), lithium hydroxide (70 mgs, 3.08 mmol) was dissolved in 
minimal amount of water (3 ml)  and was added to the reaction which was allowed to 
stir for 4 hours at room temperature. The reaction mixture was then acidified upto a 
pH of 3 using a 10% HCl solution in water and further extracted with ethyl acetate 
and washed with brine to afford the acid intermediate. The resulting acid was further 
subjected to coupling with putrescine (67 mg, .77 mmol) in the presence of 
dicyclohexylcarbodiamide in anhydrous DCM (5 mL) and was allowed to stir for 24 
h. The resulting mixture was washed with 3x with water and extracted in ethyl acetate  
followed by 3x brine wash. The ethyl acetate was concentrated in vaccum and 
purified by flash column chromatography (MeOH: DCM = 1 : 99 to 2 : 98) to give 
compound 6 (.2 g, 21%).   1H NMR (400 MHz, CDCl3) δ 0.86 (t, J =11.7, 6H), 1.26–
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1.29 (s, 50 H), 1.42-1.52 (br s, 48 H), 1.81 (br m, 4 H), 2.6 (m, 4 H), 2.96 (t, 16 H), 
3.27 (t, 4 H); 13C NMR (400 MHz, CDCl3); 14.0, 22.7, 24.6, 27.5, 28.4, 29.6, 31.8, 
33.7, 43.6, 44.7, 45.8, 46.3, 47.0, 48.6, 51.8, 79.8, 149, 156.4, 174.2; MS(ESI) 
calculated for C68H132N6O10 m/z 1193.0 found 1215.9 (MNa)+. 
 
 
 
 
Conversion of 6 to 7. The resulting Boc-protected mono-acylated polyamine (0.2 g, 
21%) was dissolved in excess (25 mL) of dry trifluoroacetic acid and stirred at room 
temperature for 45 minutes. Excess solvent was removed by purging nitrogen and the 
residue was thoroughly washed with diethyl ether to obtain white flaky solid 7 (0.170 
g, 90%). 1H NMR (400 MHz, DMSO-d6) δ 0.85 (t, J = 6.6Hz, 6H), 1.25 (br s, 56H),  
1.55-1.65 (br s, 8H), 2.55 (br m, 16H), 2.96-3 (m, 4H), 3.25 (t, 4 H); 13C NMR (400 
MHz, DMSO-d6) 16.5, 22.8, 23.0, 24.2, 25.8, 26.3, 28.9, 29.2, 29.3, 29.4, 31.7, 36.6, 
39.5, 39.7, 40.1, 40.4, 40.6, 44.3, 44.5, 46.5, 47.2, 172.5; MS(ESI) calculated for 
C48H100N6O2 m/z 792.79 found 793.8 (MH)+. 
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Conversion of 3 to 8.  To a solution of β-alanine methyl ester 3 (.5 g, 4.85 mmol) in 
DMF (10 mL) at room temperature was added triethylamine (.7 mL, 4.85 mmol) 
followed by hexadecylbromide (1.5 mL, 4.85 mmol). After removal of solvent under 
high vaccum, the alkylated derivative was purified by flash column chromatography 
(MeOH: DCM= 5 : 95 to 8 : 92) to give a colorless oil 8 (1.2 g, 75 %). 1H NMR (400 
MHz, CDCl3) δ 0.9 (s, 3 H), 1.25 (br s, 28 H), 2.55 (br m, 4 H), 2.92 (t, 2 H), 3.6 (s, 3 
H); 13C NMR (400 MHz, CDCl3); 16.9, 22.7, 28.9, 29.6, 30.1, 35.8, 48.7, 52; 
MS(ESI) calculated for C20H41NO2 m/z 327.3 found 328.3 (MH)+. 
 
 
Conversion of 8 to 9. The alkylated derivative 8 (1 g, 3.05 mmol) was further 
dissolved in 30 mL of DCM followed by addition of a solution of di-tert-butyl 
dicarbonate (3.3 g, 15.25 mmol) in a solution of DCM (10 mL). The resulting 
solution was stirred for 12 h at room temperature, concentrated in vaccum, and 
purified by flash column chromatography (EtOAc: Hexane = 13 : 87 to 15 : 85) to 
give a colorless oil 9 (0.9 g, 70 %). 1H NMR (400 MHz, CDCl3) δ 0.9 (s, 3H), 1.25 
(br s, 28 H),  1.4 (br s, 11 H), 2.55 (br t, 2 H), 2.92 (t, 2 H), 3.1 (t, 2 H), 3.67 (s, 3 H); 
13C NMR (100.6 MHz, CDCl3); 14.1, 22.7, 27, 28.9, 31.4, 33, 44, 47.1, 53, 79.4, 154, 
172.5; MS(ESI) calculated for C25H49NO4 m/z 427.37 found 450.3 (MNa)+. 
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Conversion of 9 to 10. To a stirred solution of mono-alkylated methyl ester 9 in THF 
(0.5 g, 1.17 mmol), lithium hydroxide dissolved in minimal amount of water (0.28g, 
11.7 mmol) was added and the reaction was allowed to stir for 4 hours at room 
temperature. The reaction mixture was then acidified upto a pH of 3 using a 10% HCl 
solution in water and further extracted with ethyl acetate and washed with brine to 
afford the acid intermediate. The resulting acid was further subjected to coupling with 
di-boc spermine (0.24mg, 0.58 mmol) in the presence of dicyclohexylcarbodiamide to 
obtain 10 via column chromatography (MeOH: DCM = 1 : 99 to 2 : 98) to yield (.13, 
10%).   1H NMR (400 MHz, CDCl3) δ 0.86 (t, J =11.7, 6H), 1.26–1.29 (s, 50 H), 
1.42-1.52 (br s,  48 H), 1.81 (br m, 4 H), 2.6 (m, 4 H), 2.96 (t, 12 H), 3.27 (t, 4 H), 3.5 
(t, 4 H); 13C NMR (100.6 MHz, CDCl3); 14.1, 22.7, 24.6, 27.5, 28.4, 29.6, 31.8, 33.7, 
43.6, 44.7, 45.8, 46.3, 47.0, 48.6, 51.8, 79.8, 149, 156.4, 174.2; MS(ESI) calculated 
for C68H132N6O10 m/z 1193.0 found 1215.9 (MNa)+. 
 
 
 
 
Conversion of 10 to 11. The resulting Boc-protected bis-amide-dialkylated 
polyamine was dissolved in excess (10 mL) of dry trifluoroacetic acid and stirred at 
room temperature for 45 minutes. Excess solvent was removed by purging nitrogen 
and the residue was thoroughly washed with diethyl ether to obtain white flaky solid 
7 (0.1 g, 76%). 1H NMR (400 MHz, DMSO-d6) δ 0.85 (t, J = 6.6Hz, 6H), 1.25 (br s, 
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56 H), 1.55-1.65 (br s, 8 H), 2.55 (br m, 16 H), 2.83 (t, 4 H), 3.1 (t, 4 H); 13C NMR 
(100.6 MHz, DMSO-d6) 22.8, 23.0, 24.2, 25.8, 26.3, 28.9, 29.2, 29.3, 29.4, 31.7, 
36.6, 39.5, 39.7, 40.1, 40.4, 40.6, 44.3, 44.5, 46.5, 47.2, 172.5; MS(ESI) calculated 
for C48H100N6O2 m/z 792.79 found 793.8 (MH)+. 
 
 
 
 
5.2.2 Synthesis of Mono-C16-alkylhomospermine  
Following an earlier reported procedure,107 the tri-Boc-trifluoroacetate-
polyamine 13, tri-Boc-spermine 14, di-Boc-spermine 20 were synthesized, while 
compound 16 was synthesized using literature procedure.106 
 
 
 
Conversion of 12 to 14. To a solution of compound 12 (2 g, 9.9 mmol) in methanol 
(40 mL) was added ethyl trifluroacetate (1.4 g, 9.9 mmol) and the mixture was stirred 
at -78 0C for 45 minutes. This was further allowed to stir for another 30 minutes at 
room temperature, to which then was added di-tert-butyl dicarbonate (21.6 g, 99 
mmol) and the resulting mixture was allowed to stir for 12 h. After removal of 
solvent, the residue was taken in THF: MeOH (3:1) followed by addition of solution 
of LiOH (4.75g, 20 mmol) dissolved in minimal amount of water and the resulting 
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solution was stirred for 8 h. The pH of the resulting solution was maintained over a 
pH of 12 at all times. After removal of solvent under vaccum, the desired product was 
isolated via column chromatography (MeOH: DCM: aq NH4OH = 6 : 94 :0.1) to give 
tri-Boc-spermine 14 (2.5 g, 50 %) as viscous oil.  
 
 
 
Conversion of 14 to 15. To a solution of compound 14 (0.8 g, 1.59 mmol) in 
methanol (30 mL) was added acrylonitrile (0.105 mL, 1.59 mmol) and the mixture 
stirred at room temperature for 15 h. After removal of solvent under high vaccum, the 
crude mono-nitrile derivative was dissolved in 30 ml of DCM followed by addition of 
a solution of di-tert-butyl dicarbonate (1.74 g, 7.9 mmol). The resulting solution was 
stirred for 12 h at room temperature, concentrated in vaccum, and purified by flash 
column chromatography (EtOAC: Hexane = 20 : 80 to 25 : 75) to give colorless oil 
15 (0.83 g, 80%). 1H NMR (400 MHz, CDCl3) δ 1.4 (s, 36H), 1.55 (s, 4H), 1.81 (m, 
4H), 2.67 (br s, 2H), 2.96-3.0 (br m, 12H), 3.3 (t, 2H); 13C NMR (100.6 MHz, 
CDCl3); 16.9, 17.4, 23.5, 24.6 25.8, 28.3, 36.6, 37.4, 43.5, 43.9, 44.5, 45.4, 46.5, 
46.7, 78.8, 79.4, 80.5, 118.2, 155.1, 155.4, 156.0; MS(ESI) calculated for C33H61N5O8 
m/z 655.4 found 678.4 (MNa)+. 
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Conversion of 15 to 16. A solution of mono-nitrile 15 (0.35 g, 0.53 mmol) and 
hexadecylamine (0.63 g, 2.94 mmol) in methanol (20 mL) was hydrogenated over 
Pd(OH)2/C (0.3 g) at 60 psi pressure for 12 h. The catalyst was removed by filtration 
and the residue was washed thoroughly with methanol. After removal of solvent 
under high vaccum, the crude secondary amine alkylated compound (0.41 g, 0.46 
mmol, 87%) was dissolved in methanol (30 mL) followed by the addition of a 
solution of di-tert-butyl dicarbonate (0.5 g, 2.3 mmol). The resulting solution was 
stirred for 12 h at ambient temperature, concentrated in vaccum and purified by flash 
column chromatography (EtOAC: Hexane = 17 : 83 to 20 : 80) to give compound 16 
(0.190 g, 40%) as a viscous oil. 1H NMR (400 MHz, CDCl3) δ 0.86 (t, J =11.7, 3H), 
1.26–1.29 (s, 26H), 1.42-1.52 (br s, 49H), 1.81 (br m, 6H), 3.1 (br s, 18H); 13C NMR 
(100.6 MHz, CDCl3);9.4, 14.0, 22.6, 23.4, 24.6, 26.8, 27.5, 28.0, 28.3, 29.3, 29.6, 
31.8, 33.7, 36.6, 37.2, 43.6, 44.7, 46.3, 46.7, 47.0, 76.7, 77.0, 77.4, 78.8, 79.0, 79.2, 
91.6, 155.3, 155.4, 156.0; MS(ESI) calculated for C54H105N5O10 m/z 983.7 found 
1006.7 (MNa)+. 
 
 
 
Conversion of 16 to 17. The resulting Boc-protected mono-alkylated polyamine 
(0.19g, 0.19 mmol) was dissolved in excess (25 mL) of dry trifluoroacetic acid and 
stirred at room temperature for 1 h. Excess solvent was removed by purging nitrogen 
and the residue was thoroughly washed with diethyl ether to obtain white flaky solid 
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17 (0.170 g, 90%). 1H NMR (400 MHz, DMSO-d6) δ 0.85 (t, J = 6.6Hz, 3H), 1.25 (br 
s, 26H), 1.41 (br s, 6H) 1.55-1.65 (br s, 6H), 2.88 (br m, 18H); 13C NMR (100.6 
MHz, DMSO-d6) 22.8, 23.0, 24.2, 25.8, 26.3, 28.9, 29.2, 29.3, 29.4, 31.7 , 36.6, 39.5, 
39.7, 40.1, 40.4, 40.6, 44.3, 44.5, 46.5, 47.2; MS(ESI) calculated for C29H65N5 (free 
amine) m/z 483.4 found 484.4 (MH)+. 
 
5.2.3 Large-scale synthesis of Mono-C16-alkylhomospermine  
 
 
 
Conversion of 18 to 19. To a solution of the amine 18 (4 g, 45.4 mmol) in anhydrous 
methanol (50 mL) at room temperature were added acrylonitrile (5.97 ml, 90.8 mmol) 
and the mixture stirred at room temperature for 15 h. After removal of solvent under 
high vaccum, the crude bis-nitrile derivative was dissolved in 30 ml of DCM 
followed by addition of a solution of di-tert-butyl dicarbonate (49.4 g, 227 mmol) in 
DCM (15 ml). The resulting  solution was stirred for 12 h at room temperature, 
concentrated in vaccum, and purified by flash column chromatography (EtOAC: 
Hexane = 20 : 80 to 25 : 75) to give a white flaky solid 19 (16g, 84%) 1H NMR (400 
MHz, CDCl3) δ 1.4 (s, 18H), 1.55 (s, 4H), 2.92 (br d, 4H), 3.2 (br m, 4H), 3.3 (t, 4H); 
13C NMR (100.6 MHz, CDCl3) δ 16.9, 25.88, 27.41, 46.58, 46.77, 120, 155.32, 
155.95; MS(ESI) calculated for C20H34N4O4 m/z 394.25 found 417.30 (MNa)+. 
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Conversion of 19 to 20. A solution of bis-nitrile derivative 19 (14 g, 35.5 mmol) in 
30 ml glacial acetic acid AcOH was hydrogenated over Pd(OH)2/C (0.9 g) at 60 psi 
hydrogen pressure for 12 h at room temperature. The catalyst was removed by 
filtration and the residue was washed thoroughly with methanol. After concentration 
the combined filtrate was washed with 50 ml of ammonium hydroxide. The solution 
was concentrated and left under high vaccum overnight to afford colorless oil 
compound 20 (14 g, 94%).  
 
 
Conversion of Hexadecylamine 21 to 22. To a solution of hexadecylamine (10 g, 
41.3 mmol) in anhydrous methanol (50 mL) at room temperature was added 
acrylonitrile (2.72 mL, 41.3 mmol) and the mixture stirred at room temperature for 15 
h. After removal of solvent under high vaccum, the crude bis-nitrile derivative was 
dissolved in 30 mL of DCM followed by addition of a solution of di-tert-butyl 
dicarbonate (42.95 g, 206 mmol) in DCM (15 mL). The resulting solution was stirred 
for 12 h at room temperature, concentrated in vaccum, and purified by flash column 
chromatography (EtOAc: Hexane  = 8 : 92 to 10 : 90) to give a colorless oil 22 (14g, 
89%). 1H NMR (400 MHz, CDCl3) δ 0.96 (t, 3H), 1.29 (s, 26H), 1.40-1.55 (s, 8H), 
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2.8 (br d, 2H), 3.0 (br m, 2H), 3.3 (t, 2H); 13C NMR (100.6 MHz, CDCl3) δ 14.09, 
20.90, 24.62, 25.88, 27.41, 28.35, 29.6, 31.9, 46.58, 46.77, 78.71, 79.19, 79.50, 120, 
155.32, 155.95;  MS (ESI) calculated for C24H46N2O2 m/z 394.35 found 417.30 
(MNa)+. 
 
 
 
Conversion of 20 and 22 to 23. A solution of mono-nitrile 22 (6 g, 15.2 mmol) and 
amine compound 20 (12.2 g, 30.6 mmol) in methanol (60 mL) was hydrogenated over 
Pd(OH)2/C (1 g) at 60 psi pressure for 12 h. The catalyst was removed by filtration 
and the residue was washed thoroughly with methanol. After removal of solvent 
under high vaccum, the crude secondary amine alkylated compound was dissolved in 
DCM (30 mL) followed by the addition of a solution of di-tert-butyl dicarbonate 
(16.5 g, 76 mmol) in DCM (15 mL). The resulting solution was stirred for 12 h at 
ambient temperature, concentrated in vaccum and purified by flash column 
chromatography (EtOAC: Hexane = 17 : 83 to 20 : 80) to give compound 23 (3.5g, 
40%) as a viscous oil. 1H NMR (400 MHz, CDCl3) δ 0.86 (t, J =11.7, 3H), 1.26–1.29 
(s, 26H), 1.42-1.52 (br s, 49H), 1.81 (br m, 6H), 3.1 (br s, 18H); 13C NMR (100.6 
MHz, CDCl3);9.4, 14.0, 22.6, 23.4, 24.6, 26.8, 27.5, 28.0, 28.3, 29.3, 29.6, 31.8, 33.7, 
36.6, 37.2, 43.6, 44.7, 46.3, 46.7, 47.0, 76.7, 77.0, 77.4, 78.8, 79.0, 79.2, 91.6, 155.3, 
155.4, 156.0; MS(ESI) calculated for C54H105N5O10 m/z 983.7 found 1006.7 (MNa)+. 
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Conversion of 23 to 17. The resulting Boc-protected mono-alkylated polyamine (3.4 
g, 3.45 mmol) was dissolved in excess (50 mL) of dry trifluoroacetic acid and stirred 
at room temperature for 1 h. Excess solvent was removed by purging nitrogen and the 
residue was thoroughly washed with diethyl ether to obtain white flaky solid 10 (3.2 
g, 91%). 1H NMR (400 MHz, DMSO-d6) δ 0.85 (t, J = 6.6Hz, 3H), 1.25 (br s, 26H), 
1.41 (br s, 6H) 1.55-1.65 (br s, 6H), 2.88 (br m, 18H); 13C NMR (100.6 MHz, 
DMSO-d6) 22.8, 23.0, 24.2, 25.8, 26.3, 28.9, 29.2, 29.3, 29.4, 31.7 , 36.6, 39.5, 39.7, 
40.1, 40.4, 40.6, 44.3, 44.5, 46.5, 47.2; MS(ESI) calculated for C29H65N5 (free amine) 
m/z 483.4 found 484.4 (MH)+. 
 
5.2.4 Synthesis of spermidine/spermine and norspermidine/norspermine 
analogues: 
 
 
 
Conversion of 22 to 24. Compound 22 (0.8 g, 2.02 mmol) was hydrogenated over 
Pd(OH)2/C (0.08g) at 50 psi pressure in glacial AcOH (20 mL) for 12 h. AcOH was 
removed under reduced pressure followed by addition of excess of di-tert-butyl 
dicarbonate (2.82 g, 12.9 mmol) in methanol (15 mL). After removal of solvent under 
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vaccum, the residue was purified by flash column chromatography (EtOAc: Hexane = 
2 : 98 to 4 : 96) to yield 3 as a colorless oil (0.4 g, 40%). 1H NMR (400 MHz, CDCl3) 
δ 0.90 (m, 3H), 1.25 (br s, 26H), 1.45-1.47 (m, 20H), 1.66-1.81 (m, 3H), 4.75 (br s, 
4H), 3.29 (br s, 2H); 13C NMR (100.6 MHz, CDCl3) δ 14.13, 22.70, 26.89, 28.46, 
29.37, 29.60, 29.63, 29.66, 29.70, 31.93; MS(ESI) calculated for C29H58N2O4 m/z 
498.44 found 521.50 (MNa)+ 
 
 
 
Conversion of 24 to 25. Compound 24 (0.4 g, 0.8 mmol)  was dissolved in excess of 
dry trifluoroacetic acid (25 mL) and stirred at room temperature for 30 min. Excess 
solvent was removed by purging nitrogen and the residue was thoroughly washed 
with diethyl ether to obtain white flaky solid 25 (0.3 g, 71.4%). 1H NMR (400 MHz, 
DMSO-d6) δ 0.87 (m, 3H), 1.24 (br s, 26H), 1.58 (br s, 2H), 1.89 (m, 2H), 2.89 (m, 
4H), 2.99 (m, 2H); 13C NMR (100.6 MHz, DMSO-d6) δ 14.41, 22.55, 24.13, 25.80, 
26.32, 28.96, 29.16, 29.24, 29.38, 29.50, 31.75, 36.50, 44.20, 47.15, 116.17, 119.15, 
158.65, 158.96; MS(ESI) calculated for C19H42N2 (free amine) m/z 298.33 found 
299.38 (MH)+. 
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Conversion of 22 to 26. A solution of mono-nitrile 22 (0.57 g, 1.45 mmol) and 1, 4-
diaminobutane (1.02 g, 11.6mmol) in methanol (25 mL) was hydrogenated over 
Pd(OH)2/C (0.05g) at 60 psi pressure for 12 h. The catalyst was removed by filtration 
and the residue was washed thoroughly with methanol. After removal of solvent 
under high vaccum, the crude amine alkylated compound (0.33 g, 0.70 mmol, 49.3%) 
was dissolved in methanol (20 mL) to which a solution of di-tert-butyl dicarbonate 
(1.53 g, 7.0 mmol) in methanol (5 mL) was added. The resulting solution was stirred 
for 12 h at ambient temperature, concentrated in vaccum and purified by flash column 
chromatography (EtOAc: Hexane = 8 : 92 to 10 : 90 ) to give compound 26 (0.35 g, 
74.5%) as a viscous oil. 1H NMR (400 MHz, CDCl3) δ 0.82 (m, 3H), 1.19 (br s, 26H), 
1.39 (m, 33H), 1.66 (br s, 2H), 3.10 (br s, 10H); 13C NMR (100.6 MHz, CDCl3) δ 
14.03, 22.59, 25.54, 26.77, 27.32, 28.33, 28.39, 29.27, 29.32, 29.50, 29.57, 29.60, 
31.84, 40.13, 44.33, 44.66, 46.60, 47.04, 78.78, 78.97, 79.15, 155.39, 155.93; 
MS(ESI) calculated for C38H75N3O6 m/z 669.57 found 692.61 (MNa)+. 
 
 
 
Conversion of 26 to 27. The resulting Boc-protected polyamine 26 (0.35 g, 0.70 
mmol) was dissolved in excess of dry trifluoroacetic acid (25 mL) and stirred at room 
temperature for 30 min. Excess solvent was removed by purging nitrogen and the 
residue was thoroughly washed with diethyl ether to obtain white flaky solid 27 (0.3 
g, 81%). 1H NMR (400 MHz, DMSO-d6) 0.86 (m, 3H), 1.24 (br s, 26H), 1.56-1.62 
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(m, 6H), 1.96 (m, 2H), 2.80-2.99 (m, 10H), 8.79-8.90 (m, 4H); 13C NMR (100.6 
MHz, DMSO-d6) 14.40, 22.55, 22.79, 23.00, 24.59, 25.84, 26.33, 28.95, 29.16, 29.23, 
29.37, 29.46, 29.50, 31.75, 38.66, 44.30, 44.34, 46.55, 47.20, 116.09, 119.07, 158.58, 
158.89, 159.21; MS(ESI) calculated for C23H51N3 (free amine) m/z 369.41 found 
370.45 (MH)+. 
 
 
Conversion of 14 to 28 (synthesized by Dr. Rongti Li). To a solution of the 
Compound 14 (0.989 g, 1.97 mmol) [which was synthesized from spermine 7 using a 
reported procedure (J. Med. Chem. 2107; 50(4); 877-888)] was added acetic acid (0.7 
mL) in dry methanol (30 mL) followed by the addition of hexadecylaldehyde (0.315 
g, 1.31 mmol), and also the addition of sodium cyanoborohydride (0.124 g, 0.1.97 
mmol) in one portion. The colorless solution was stirred at room temperature for 24 h. 
The reaction was quenched by the addition of concentrated HCl to pH 2, followed by 
basification of the resulting solution to pH 12 by addition of solid NaOH. The 
solution was concentrated under reduced pressure, and the residue was extracted with 
ether (3 x 50 mL). The combined organic layers were washed with saturated aqueous 
sodium chloride and dried over anhydrous Na2SO4. Removal of solvent and 
purification of the crude product by column chromatography 
(CH2Cl2/MeOH/aq.ammonia = 9 : 1 : 0.05) provided the compound 28 as a colorless 
oil (0.655g, 69%). 1H NMR (CDCl3, 400 MHz) δ 3.27-3.12 (m, 10H), 2.62 (br s, 4H), 
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1.74-1.66 (m, 4H), 1.50-1.32 (br s, 34H), 1.32-1.23 (m, 27H), 0.89 (t, J = 8.0 Hz, 
3H); 13C NMR (CDCl3, 125 MHz) δ 156.1(3C), 79.5, 50.1, 46.8, 46.5, 44.2, 37.4, 
31.9, 30.1, 29.69, 29.65, 29.62, 29.60, 29.56, 29.36, 28.5, 27.4, 26.1, 25.6, 22.7, 14.1; 
HRMS (ESI, m/z) calculated for C41H83N4O6 (MH+) 727.6312, found 727.6307. 
 
 
 
Conversion of 28 to 29 (synthesized by Dr. Rongti Li). The Boc-protected 
monoalkyl polyamine 28 (0.64 g, 0.88 mmol) was dissolved in dry trifluoroacetic 
acid (10 mL) and the solution stirred at room temperature for 20 h. Excess solvent 
was removed under reduced pressure, and the residue was thoroughly triturated with 
dichloromethane and diethyl ether to provide the product 29 as a white flaky solid 
(0.609 g, 90%). 1H NMR (DMSO-d6, 400 MHz) δ 8.86-8.73 (m, 3H), 7.93 (br s, 2H), 
2.99-2.92 (m, 14H), 1.93 (br s, 4H), 1.64-1.58 (m, 6H), 1.26 (br s, 26H), 0.86 (t, J = 
8.0 Hz, 3H); 13C NMR (DMSO-d6, 125 MHz) δ 158.7, 158.4, 158.2, 64.9, 46.7, 46.1, 
43.9, 36.2, 31.3, 29.0, 28.9, 28.7, 28.6, 28.5, 25.8, 25.4, 23.8, 22.6, 22.3, 22.1, 13.1; 
HRMS (ESI, m/z) calculated for C26H59N4 (MH+) 427.4740, found 427.4738. 
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Conversion of 20 to 30. To a solution of compound 20 (1.0 g, 2.48 mmol) in 
methanol (50 mL) was added acrylonitrile (0.26 g, 5 mmol) and stirred at room 
temperature for 15 h. After removal of solvent under high vacuum, the crude bis-
nitrile derivative (1.2 g, 95 %) was dissolved in DCM (30 mL) followed by the 
addition of a solution of di-tert-butyl dicarbonate (1.05 g, 4.8 mmol) in DCM (10 
mL).  The resulting solution was stirred for 90 min at ambient temperature, 
concentrated in vacuo and purified by flash column chromatography (EtOAc: Hexane 
= 40 : 60) to give compound 6 (1.12 g, 64 %) as a viscous oil. 1H NMR (400 MHz, 
CDCl3) δ 1.45 and 1.47 (2s, 42H), 1.72-1.79 (m, 4H), 2.55-2.68 (m, 4H), 3.08-3.20 
(br s, 6H), 3.21-3.30 (m, 4H), 3.46-3.51 (m, 4H); 13C NMR (100.6 MHz, CDCl3) δ 
17.0, 17.6, 25.6, 26.0, 28.4, 28.5, 43.5, 44.0, 44.6, 45.5, 46.6, 47.0, 79.5, 80.6, 154.7, 
155.2, 155.5; MS (ESI) calculated for C36H64N6O8 m/z 708.4, found 709.5 (MH)+. 
 
 
 
 
 
Conversion of 30 to 31. 1.5 g of  compound 30 was hydrogenated over 0.15g of 
Pd(OH)2/C  at 60 psi pressure in glacial AcOH (20 mL) for 12 h. AcOH was removed 
under reduced pressure followed by addition of excess of di-tert-butyl dicarbonate 
(2.3 g, 10.5 mmol) in methanol (15 mL) to afford 31 as colorless oil (0.6 g). Yield 
31%; 1H NMR (400 MHz, CDCl3) δ 1.34 (br s, 54H), 1.56 (br s, 4H), 1.63 (br s, 8H), 
2.90-3.06 (m, 15H), 3.06-3.15 (m, 5H); 13C NMR (100.6 MHz, CDCl3) δ 14.09, 
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20.90, 24.62, 25.88, 27.41, 28.35, 37.31, 43.69, 44.70, 46.58, 46.77, 60.22, 78.71, 
79.19, 79.50, 155.32, 155.95; MS(ESI) calculated for C46H88N6O12 m/z 916.65 found 
939.64 (MNa)+. 
 
 
 
Conversion of 31 to 32. 0.34 g (0.4 mmol) of compound 31 was added to the 
suspension of 60% NaH (0.2 g, 8.3 mmol)  in DMF and was stirred for 10 min at 0oC 
after which 0.14 g of iodohexadecane (0.4 mmol) was added and thereafter was 
stirred for 24h. The reaction mixture was quenched with 10% HCl and extracted with 
EtOAc. After removal of the solvent under reduced pressure, the desired Boc-
protected, mono-alkylated compound (0.11 g, 26.2%) was isolated at (EtOAc: 
Hexane = 20 : 80). 1H NMR (400 MHz, CDCl3) δ 0.70-0.73 (br s, 3H), 1.25 (br s, 
26H), 1.44-1.46 (m, 54H), 1.54-1.73 (m, 14H), 3.15-3.47 (m, 22H); 13C NMR (100.6 
MHz, CDCl3) δ 14.11, 22.67, 25.82, 26.86, 28.44, 28.47, 29.34, 29.41, 29.59, 29.64, 
29.67, 31.90, 37.32, 44.79, 47.07, 79.08, 79.31, 155.42, 156.05; MS(ESI) calculated 
for C62H120N6O12 m/z 1140.89 found 1163.77 (MNa)+. 
 
 
 
Conversion of 32 to 33. 0.11 g of Compound 32 was dissolved in excess of dry 
trifluoroacetic acid (25 mL) and stirred at room temperature for 30 min. Excess 
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solvent was removed by purging nitrogen and the residue was thoroughly washed 
with diethyl ether to obtain white flaky solid 33 (0.053g, 37.8 %). 1H NMR (400 
MHz, DMSO-d6) δ 0.84-0.87 (m, 3H), 1.26 (br s, 26H), 1.86-1.96 (m, 8H), 2.92-2.99 
(m, 22H), 8.9-9.01 (m, 7H); 13C NMR (100.6 MHz, DMSO-d6) 14.41, 22.55, 22.87, 
23.13, 24.30, 25.86, 26.33, 28.95, 29.16, 29.37, 29.50, 31.75, 36.63, 44.35, 44.53, 
46.61, 47.21, 158.95, 159.26; MS(ESI) calculated for C32H72N6 (free amine) m/z 
540.58 found 541.52 (MH)+. 
 
 
 
Conversion of 34 to 35. To a solution of norspermidine 34 (0.5 g, 3.81 mmol) in 
methanol (20 mL), di-tert-butyl dicarbonate (8.4 g, 38.1 mmol) dissolved in methanol 
(5 mL) was added.  The resulting solution was stirred for 12 h at ambient 
temperature, concentrated in vaccum and purified by flash column chromatography 
(EtOAc: hexane = 20 : 80 to 25 : 75) to afford the Boc protected product 35 (1.4 g, 85 
%) as a viscous oil. 1H NMR (400 MHz, CDCl3) δ 1.38 (s, 27H), 1.86 (m, 4H), 3.0 (t, 
4H) 3.2 (t, 4H); 13C NMR (100.6 MHz, CDCl3) δ 28.4, 37.5, 44.1, 79.8, 156; 
MS(ESI) calculated for C21H41N3O6 m/z 431.3 found 454.2 (MNa)+. 
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Conversion of 35 to 36. A solution of 35 (1.4 g, 3.24 mmol) and 60% of sodium 
hydride suspension (6.25 g, 259.8 mmol) in DMF (20 mL) was cooled to -15 oC and 
hexadecyl iodide (1.14 g, 3.24 mmol) was then added to it dropwise under nitrogen 
atmosphere. The resulting mixture was stirred for another 1 h at -15 oC and was 
allowed to stir overnight at room temperature. The reaction mixture was quenched 
with 10% HCl solution in water, extracted with EtOAc, dried with Na2SO4 and 
concentrated. The residue was purified by flash column chromatography (EtOAc: 
hexane = 8 : 92 to 10 : 90) to afford 36 (0.5 g, 24%) as a viscous oil. 1H NMR (400 
MHz, CDCl3) δ 0.9 (t, 3H), 1.27 (br s, 25H), 1.38 (s, 27H), 1.86 (m, 4H), 3.0 (t, 6H) 
3.2 (t, 2H); 13C NMR (100.6 MHz, CDCl3) δ 14.1, 22.7, 24.1, 26.3, 27, 28.4, 29.3, 
29.6, 31.8, 39.9, 45.7, 46, 48.6, 79.8, 156; MS(ESI) calculated for C37H73N3O6 m/z 
655.5 found 678.5 (MNa)+. 
 
 
 
Conversion of 36 to 37. The resulting product 36 was dissolved in excess (25 mL) of 
dry trifluoroacetic acid and stirred at room temperature for 45 minutes. Excess 
solvent was removed by purging nitrogen and the residue was thoroughly washed 
with diethyl ether to obtain white flaky solid 37 (0.35 g, 70%). 1H NMR (400 MHz, 
DMSO-d6) δ 0.88 (t, J = 6.6Hz, 3H), 1.29-1.38 (s, 25H), 1.55 (br m, 2H) 1.75 (br m, 
4 H), 2.55 (t, 4 H), 2.65 (t, 6 H); 13C NMR (100.6 MHz, DMSO-d6) δ 14.1, 22.7, 
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24.1, 26.3, 27, 27.3, 29.3, 29.6, 30.5, 31.8, 39.4, 45.7, 46, 46.3, 49.9; MS(ESI) 
calculated for C22H49N3 m/z 355.3 found 356.4 (MH)+. 
 
 
 
Conversion of 38 to 39. To a solution of norspermine 38 (0.5 g, 2.65 mmol) in 
methanol (20 mL) di-tert-butyl dicarbonate (5.8 g, 26.5 mmol) dissolved in methanol 
(7 mL) was added. The resulting solution was stirred for 12 h at ambient temperature, 
concentrated in vaccum and purified by flash column chromatography (EtOAc: 
hexane = 15 : 85) to afford the Boc protected product 39 (1.3 g, 83 %) as a viscous 
oil. 1H NMR (400 MHz, MeOD) δ 1.5 (s, 36H), 1.86 (m, 4H), 3.0 (t, 4H) 3.2 (t, 8H); 
13C NMR (100.6 MHz, CDCl3) δ 26, 28.4, 37.5, 44.1,  47.6, 79.6, 156; MS(ESI) 
calculated for C29H56N4O8 m/z 588.41 found 611.39 (MNa)+. 
 
 
 
Conversion of 39 to 40. A solution of 39 (1 g, 1.7 mmol) and 60% sodium hydride 
(3.26 g, 136 mmol) in DMF (30 mL) was cooled to -15 oC and hexadecyl iodide (0.6 
g, 1.7 mmol) was then added to it dropwise under nitrogen atmosphere. The resulting 
mixture was stirred for another 1 h at -15 oC and was allowed to stir overnight at 
room temperature. The reaction mixture was quenched with 10% HCl solution in 
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water, extracted with EtOAc, dried with Na2SO4 and concentrated. The residue was 
purified by flash column chromatography (EtOAc: hexane = 10 : 90) to afford 40 
(0.35 g, 25%) as a viscous oil. 1H NMR (400 MHz, CDCl3) δ 0.9 (t, 3H), 1.27 (br s, 
25H), 1.38 (s, 27H), 1.86 (m, 4H), 3.0 (t, 6H) 3.2 (t, 2H); 13C NMR (100.6 MHz, 
CDCl3) δ 14.1, 22.7, 24.1, 26.3, 27, 28.4, 29.3, 29.6, 31.8, 39.9, 45.7, 46, 48.6, 79.8, 
156; MS(ESI) calculated for C45H88N4O8 m/z 812.6 found 835.64 (MNa)+. 
 
 
 
Conversion of 40 to 41. The resulting product 40 was dissolved in excess (25 mL) of 
dry trifluoroacetic acid and stirred at room temperature for 8 h. Excess solvent was 
removed by purging nitrogen and the residue was thoroughly washed with diethyl 
ether to obtain white flaky solid 41 (0.21 g, 90%). 1H NMR (400 MHz, DMSO-d6) δ 
0.88 (t, J = 6.6Hz, 3H), 1.29-1.38 (s, 25H), 1.55 (br m, 2H) 1.75 (br m, 4 H), 3.0 (t, 
12 H); 13C NMR (100.6 MHz, DMSO-d6) δ 14.1, 22.7, 24.1, 26.3, 27, 27.3, 29.3, 
29.6, 30.5, 31.8, 39.4, 45.7, 46, 46.3, 49.9; MS(ESI) calculated for C25H56N4 m/z 
412.4 found 413.49 (MH)+. 
 
 
 
 
Conversion of 34 to 42. To a solution of amine 34 (3 g, 22.9 mmol) in methanol (50 
mL) at -78 oC was added dropwise ethyl trifluoroacetate (2.72 mL, 22.9 mmol) over 
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30 min and the solution was stirred for another 30 min. The temperature was raised to 
0 oC and an excess of di-tert-butyl dicarbonate (40.0 g, 183.2 mmol) in methanol (20 
mL) was added over 10 min. The reaction was then warmed to 25 oC for 15 h. After 
removal of solvent under vaccum, the crude product was dissolved in THF (20 mL) 
followed by addition of a solution of lithium hydroxide (5.5 g, 229 mmol) in water 
(40 mL). The resulting solution was stirred at ambient temperature for 24 h. The 
reaction mixture was extracted with chloroform. The combined extracts were washed 
with water and brine and dried over sodium sulfate. After removal of solvent under 
vacuum, the residue was purified by flash column chromatography with use of 
(MeOH : DCM = 4 : 96 to 6 : 94) to afford the product 42 as colorless viscous oil (5 
g, 15.1 mmol) in 67 % yield.1H NMR (400 MHz, CDCl3) δ 1.44-1.47 (m, 18H), 2.74-
2.79 (m, 4H), 3.10-3.11 (br s, 2H), 3.24-3.47 (m, 6H); 13C NMR (100.6 MHz, 
CDCl3); 28.34, 28.40, 80.49, 156.12; MS(ESI) calculated for C16H33N3O4 m/z 331.24 
found 332.23 (MH)+. 
 
Conversion of 43 to 44. To a solution of 3-aminopropanenitrile 43 (2.08 mL, 28.6 
mmol) in dry DMF and K2CO3 (6 g, 43.5 mmol) was added 3-bromopropan-1-ol 
(2.49 mL, 28.6 mmol) and the reaction mixture was refluxed for 12 h. After removal 
of DMF under reduced pressure, an excess of di-tert-butyl dicarbonate (24.9 g, 114.2 
mmol) in methanol (20 ml) was added and the resulting solution was stirred at 
ambient temperature for 24 h. After removal of solvent under vacuum, the residue 
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was purified by flash column chromatography at (EtOAc: Hexane = 20 : 80) to afford 
the product 44 as colorless viscous oil (5 g, 76.9%). 1H NMR (400 MHz, CDCl3) δ 
1.5 (br s, 9H), 1.66-1.79 (m, 2H), 2.61-2.68 (m, 2H), 3.31-3.49 (m, 4H), 3.59-3.68 
(m, 2H); 13C NMR (100.6 MHz, CDCl3); 17.44, 28.30, 30.66, 43.53; MS (ESI) 
calculated for C11H20N2O3 m/z 228.14 found 251.14 (MNa)+. 
 
 
 
 
Conversion of 42 and 44 to 45. A solution of mono-nitrile 44 (2.19 g, 9.6 mmol) and 
tris-amine 42 (1.31 g, 3.9 mmol) in methanol (20 mL) was hydrogenated over 
Pd(OH)2/C (0.3 g) at 60 psi pressure for 12 h. The catalyst was removed by filtration 
and the residue was washed thoroughly with methanol. After removal of solvent 
under high vaccum, the crude secondary amine compound (2.0 g, 3.7 mmol, 92%) 
was dissolved in methanol (30 mL) followed by the addition of a solution of di-tert-
butyl dicarbonate (16.4 g, 75.14 mmol) in methanol (7 mL). The resulting solution 
was stirred for 12 h at ambient temperature, concentrated in vaccum and purified by 
flash column chromatography at (EtOAc: Hexane = 35 : 65 to  38 : 62) to give the 
product 45 (2.0 g, 84.7%) as a viscous oil . 1H NMR (400 MHz, CDCl3) δ 1.25-1.27 
(m, 36H), 1.43-1.57 (m, 8H), 2.91-3.16 (m, 14H), 3.37 (br s, 2H); 13C NMR (100.6 
MHz, CDCl3); 20.79, 28.25, 28.28, 29.45, 30.58, 31.69, 36.11, 36.51, 37.55, 42.82, 
44.88, 50.39, 53.44, 58.31, 59.51, 60.12, 62.01, 78.61, 79.29, 79.44, 79.75, 81.73, 
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86.66, 87.97, 89.65, 91.87, 92.70, 96.85, 98.04, 114.45, 117.31, 155.18, 155.74, 
155.95, 156.42, 156.95, 170.83; MS(ESI) calculated for C32H62N4O9 m/z 646.45 
found 669.46 (MNa)+. 
 
 
 
Conversion of 45 to 46. A solution of the alcohol 45 (1.35 g, 2.08 mmol) and PCC (1 
g, 4.32 mmol) in dry DCM was stirred for 3 h. After removal of the solvent under 
reduced pressure the crude product was purified by column chromatography (EtOAC: 
Hexane = 30 : 70 to  35 : 65) to give the product 46 (0.46 g, 34.3%) as a viscous oil. 
1H NMR (400 MHz, CDCl3) δ 1.38 (br s, 36H), 1.46-1.82 (m, 8H), 3.04-4.08 (m, 
14H), 9.73 (s, 1H); 13C NMR (100.6 MHz, CDCl3); 24.21, 24.55, 24.63, 27.51, 28.37, 
28.90, 36.60, 37.00, 37.32, 43.67, 44.77, 78.78, 79.44, 79.60, 91.62, 155.31, 156.07, 
197; MS(ESI) calculated for C32H60N4O9 m/z 644.44 found 667.45 (MNa)+. 
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Conversion of 46 to 47. To a solution of 0.46 g of the aldehyde 46 and 
hexadecylamine (0.26 g, 1.08 mmol) in absolute methanol (20 mL), sodium 
cyanoborohydride (.09 g, 1.43 mmol) and 5-6 drops of glacial acetic acid was added. 
The reaction mixture was allowed to stir at room temperature for 24 h. After removal 
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of the solvent under reduced pressure the crude product was purified by column 
chromatography (MeOH: DCM = 1 : 99) to give the alkylated secondary amine (0.51 
g, 0.58 mmol, 82.3%)  was dissolved in a solution of methanol (20 mL) to which a 
solution of di-tert-butyl dicarbonate (1.3 g, 5.9 mmol) in methanol (10 mL) was 
added. The resulting solution was stirred for 12 h at ambient temperature, 
concentrated in vaccum and purified by flash column chromatography (EtOAc: 
Hexane = 20 : 80 to 25 : 75) to give the product 47 (0.52 g, 92.8%) as a viscous oil . 
1H NMR (400 MHz, MeOD) δ 0.91-0.94 (m, 3H), 1.32 (br s, 28H), 1.46-1.55 (m, 
45H), 1.71-1.78 (m, 8H), 3.04-3.09 (m, 2H), 3.22-3.33 (m, 16H); 13C NMR (100.6 
MHz, MeOD); 19.61, 22.43, 26.55, 27.58, 27.91, 28.29, 29.17, 29.37, 29.40, 29.48, 
31.76, 37.64, 44.50, 44.82, 60.09, 78.22, 78.42, 79.31, 79.52, 79.55, 79.72, 155.67, 
155.81, 156.96; MS(ESI) calculated for C53H103N5O10 m/z 969.77 found 992.80 
(MNa)+. 
 
 
 
Conversion of 47 to 48. The polyamine 47 (0.52 g, 0.54 mmol) was dissolved in 
excess of dry trifluoroacetic acid (20 mL) and stirred at room temperature for 30 min. 
Excess solvent was removed by purging nitrogen and the residue was thoroughly 
washed with diethyl ether to obtain white flaky solid 48 (0.31 g, 56.3%). 1H NMR 
(400 MHz, DMSO-d6) δ 0.84-0.86 (m, 3H), 1.24 (br s, 26H), 1.56-1.73 (br s, 2H),  
1.89-2.13 (br s, 8H), 2.67-2.88 (m, 18H), 8.98-9.09 (m, 6H); 13C NMR (100.6 MHz, 
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DMSO-d6); 22.55, 28.95, 29.50, 31.75, 44.52 MS(ESI) calculated for C28H63N5 m/z 
469.51 (free amine) found 470.51 (MH)+. 
 
 
 
Conversion of 38 to 49. To a solution of norspermine 38 (1 g, 5.31 mmol) in 
methanol (30 mL) at -78 oC was added dropwise ethyl trifluoroacetate (1.26 mL, 
10.62 mmol) over 30 min and the solution was stirred for another 1 h. The 
temperature was then increased to 0 oC and an excess of di-tert-butyl dicarbonate 
(11.6 g, 53.1 mmol) in methanol (10 mL) was added over 10 min. The reaction was 
then warmed to room temperature and stirred for another 20 h. After removal of 
solvent under high vaccum, the crude product was dissolved in THF (30 mL) 
followed by addition of a solution of lithium hydroxide (.38 g, 15.93 mmol) in water 
(10 mL). The resulting solution was stirred at ambient temperature for 24h. The 
reaction mixture was extracted with chloroform (4 x). The combined extracts were 
washed with water (1 x) and brine (1 x), dried over Na2SO4. After removal of solvent 
under vaccum, the residue was purified by flash column chromatography (MeOH: 
DCM: aq NH4OH = 1 : 9 : 0.1) to afford the title compound 49 as a viscous oil (.41 g, 
20.4%).1H NMR (400 MHz, CDCl3) δ 1.25 (s, 18H), 1.47 (t, 4H), 1.55 (br t, 2H), 2. 
47 (t, 4H), 2.9 (br s, 4H), 3.0 (br s, 4H); 13C NMR (100.6 MHz, CDCl3) δ 28.45, 31.2, 
32.1,   38.7, 39, 43.7, 44.1,  49.2, 77.6, 79. 18, 156.0; MS(ESI) calculated for 
C19H40N4O4 m/z 388.30 found 389.30 (MH)+. 
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Conversion of 49 to 50. To a solution of the amine 49 (0.4 g, 1.05 mmol) in 
anhydrous methanol (15 mL) at room temperature was added acrylonitrile (0.14 mL, 
2.11 mmol) and the mixture stirred at room temperature for 15 h. After removal of 
solvent under high vaccum, the crude bis-nitrile derivative was dissolved in 15 mL of 
DCM to which a solution of di-tert-butyl dicarbonate (2.28 g, 10.5 mmol) in DCM (7 
mL) was added. The resulting solution was stirred for 12 h at room temperature, 
concentrated in vaccum, and purified by flash column chromatography (EtOAc: 
Hexane = 17: 83 to 20 : 80) to give a white flaky solid 50 (0.35 g, 48 %) 1H NMR 
(400 MHz, CDCl3) δ 1.33 (s, 36H), 1.64 (br m, 6H), 2.5 (br d, 4H), 3.06 (br s, 8H), 
3.1 (t, 4H), 3.3 (t, 4H); 13C NMR (100.6 MHz, CDCl3) δ 16.80, 20.9, 44.61, 45.2, 
46.34, 80.3, 118.2, 155.21 MS(ESI) calculated for C35H62N6O8 m/z 694.46 found 
717.39 (MNa)+. 
 
 
 
 
Conversion of 50 to 51. A solution of bis-nitrile 50 (0.35 g, 0.50 mmol) in glacial 
AcOH (10 mL) was hydrogenated over Pd(OH)2/C (0.1 g) at 60 psi pressure for 12 h. 
The catalyst was removed by filtration and the residue was washed thoroughly with 
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methanol. After removal of solvent under high vaccum, the amine was reacted with 
excess di-tert-butyl dicarbonate (1.1 g, 5 mmol). The resulting solution was stirred for 
12 h at ambient temperature, concentrated in vaccum and purified by flash column 
chromatography (EtOAc: Hexane = 15: 75 to 20 : 80) to give compound 51 (0.225 g, 
50%) as a viscous oil. 1H NMR (400 MHz, CDCl3) δ 1.44 (s, 54H), 1.64 -1.72 (br m, 
10H), 3.0 (t, 18H), 3.23 (t, 4H); 13C NMR (100.6 MHz, CDCl3); 28.4, 37.27, 44.73, 
77.37, 79.45, 155.34; MS(ESI) calculated for C45H86N6O12 m/z 902.63 found 925.51 
(MNa)+. 
 
 
 
 
Conversion of 51 to 52. A solution of 51 (0.2 g, 0.22 mmol) and 60% sodium 
hydride (0.42 g, 17.73 mmol) in DMF (10 mL) was cooled to -15 oC and hexadecyl 
iodide (0.6 g, 0.22 mmol) was then added to it dropwise under nitrogen atmosphere. 
The resulting mixture was stirred for another 1 h at -15 oC and was allowed to stir 
overnight at room temperature. The reaction mixture was quenched with 10% HCl 
solution in water, extracted with EtOAc, dried with Na2SO4 and concentrated. The 
residue was purified by flash column chromatography (EtOAc: Hexane = 30 : 70 to 
35 : 65) to afford 52 (62 mg, 25%) as a viscous oil. 1H NMR (400 MHz, CDCl3) δ 0.9 
(t, 3H), 1.27 (br s, 28H), 1.38 (s, 54H), 1.86 (m, 12H), 3.0 (t, 22H); 13C NMR (100.6 
N
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MHz, CDCl3) δ 14.1, 22.7, 24.1, 26.3, 27, 28.4, 29.3, 29.6, 31.9, 44.80, 77.33, 
155.38; MS(ESI) calculated for C61H118N6O12 m/z 1126.88 found 1149.7 (MNa)+. 
 
 
Conversion of 52 to 53. The resulting product 52 (60 mg, .05 mmol) was dissolved 
in excess (10 mL) of dry trifluoroacetic acid and stirred at room temperature for 45 
min. Excess solvent was removed by purging nitrogen and the residue was thoroughly 
washed with diethyl ether to obtain white flaky solid 53 (30 mg, 50%). 1H NMR (400 
MHz, DMSO-d6) δ 0.88 (t, J = 6.6Hz, 3H), 1.29-1.38 (s, 25H), 1.55 (br m, 2H) 1.75 
(br m, 6 H), 3.0 (t, 12 H); 13C NMR (100.6 MHz, DMSO-d6) δ 14.1, 22.7, 24.1, 26.3, 
27, 27.3, 29.3, 29.6, 30.5, 31.8, 39.4, 45.7, 46, 46.3, 49.9; MS(ESI) calculated for 
C31H70N6 m/z 526.57 found 527.56 (MH)+. 
 
 
 
 
 
 
 
 
H
N
H
N
H
N
H
N
H
N
NH2
.6CF3CO2H53
C16H33
 96
5.2.5 Rapid-throughput Fluorescence Displacement Assay for Quantifying 
Binding Affinities to LPS: The BODIPY-TR-cadaverine (BC; (5-(((4-(4,4-difluoro-
5-(2-thienyl)-4-bora-3a,4a-diaza-s-indacene-3-yl)phenoxy)acetyl)amino)pentylamine, 
hydrochloride; obtained from Molecular probes, Inc., Eugene, OR) displacement 
assay to quantify the affinities of binding of compounds to LPS has been described in 
detail recently.108 This assay was performed in a rapid-throughput format as follows. 
The first column (16 wells) of a Corning Nonbinding Surface 384-well flat-bottom 
black fluorescence microplate contained 15 test compounds plus polymyxin B, all at 
5 mM in DMSO, and were serially diluted two-fold in 50 mM Tris buffer, pH 7.4, 
across the remaining 23 columns, achieving a final dilution of 0.596 nM in a volume 
of 40 μl. Polymyxin B (PMB), a peptide antibiotic known to bind and neutralize 
LPS134 served as the positive control and reference compound for every plate, 
enabling the quantitative assessment of repeatability and reproducibility (CV and Z’ 
factors) for the assay. Automated robotic liquid handling was performed on a 
Precision 2000 automated microplate pipetting system, programmed using the 
Precision Power software, Bio-Tek Instruments Inc., VT, USA. Stock solutions of 
LPS (5 mg/ml; E. coli 0111:B4; procured from Sigma) and BC (500 μM) were 
prepared in Tris buffer (pH 7.4, 50 mM). LPS and BC stocks (1 ml each) were mixed 
and diluted in Tris buffer to a final volume of 100 ml, yielding final concentrations of 
50 μg/ml of LPS and 5 μM BC. Forty μl of this BC:LPS mixture was added to each 
well of the plate using the Precision 2000. Fluorescence measurements were made at 
25°C on a Fluoromax-3 with Micromax Microwell 384-well plate reader using 
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DataMax software, Jobin Yvon Inc., NJ.  The BC excitation wavelength was 580 nm, 
and emission spectra were taken at 620 nm with both emission and excitation 
monochromator bandpasses set at 5 nm. The fluorescence of BC is quenched upon 
binding to LPS, and the displacement of BC by the compounds results in de-
quenching (intensity enhancement) of BC fluorescence. Effective displacements 
(ED50) were computed at the midpoint of the fluorescence signal versus compound 
concentration displacement curve, determined using an automated four-parameter 
sigmoidal fit utility of the Origin plotting software (Origin Lab Corp., MA).  Z’ 
factors135 were computed using the equation: 1-[3(SD+SD’)/(A-A’)] where SD and 
SD’, A and A’ are standard deviations for the signal and noise, and means of signal 
and noise, respectively. A Z’ factor of 0.821 and an inter-plate CV of 5.2% were 
obtained.  
5.2.6 NF-κB induction: The induction of NF-κB (a key transcriptional activator of 
the innate immune system) was quantified using HEK-Blue-4™ cells. Stable 
expression of secreted alkaline phosphatase (sAP) under control of NF-κB/AP-1 
promoters is inducible by LPS, and extracellular sAP in the supernatant is 
proportional to NF-κB induction. HEK- Blue-4™ cells were incubated at a density of 
~105 cells/ml in a volume of 80 µl/well, in 384-well, flat-bottomed, cell culture-
treated microtiter plates until confluency was achieved, and subsequently graded 
concentrations of stimuli.  sAP was assayed spectrophotometrically using an alkaline 
phosphatase-specific chromogen (present in HEK-detection medium as supplied by 
the vendor) at 620 nm.  
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5.2.7 Nitric Oxide Assay: Nitric oxide production was measured as total nitrite in 
murine macrophage J774A.1 cells using the Griess assay136 as described.137 J774A.1 
cells were plated at ~105/ml in a volume of 40 µl/well, in 384-well, flat-bottomed, 
cell culture treated microtiter plates and subsequently stimulated with 10 ng/ml 
lipopolysaccharide (LPS). Concurrent to LPS stimulation, serially diluted 
concentrations of test compounds were added to the cell medium and left to incubate 
overnight for 16 h. Polymyxin B was used as reference compound in each plate. 
Positive- (LPS stimulation only) and negative-controls (J774A.1 medium only) were 
included in each experiment. Nitrite concentrations were measured by adding 40 μl of 
supernatant to equal volumes of Griess reagents (50 µl/well; 0.1% NED solution in 
ddH2O and 1% sulfanilamide, 5% phosphoric acid solution in ddH2O) and incubating 
for 15 minutes at room temperature in the dark.  Absorbance at 535 nm was measured 
using a Molecular Devices Spectramax M2 multifunction plate reader (Sunnyvale, 
CA). Nitrite concentrations were interpolated from standard curves obtained from 
serially diluted sodium nitrite standards. 
5.2.8 Phosflow™ flow cytometric assay for p38MAPK: One ml aliquots of fresh 
whole blood, anticoagulated with heparin (obtained by venipuncture from healthy 
human volunteers with informed consent and as per guidelines approved by the 
Human Subjects Experimentation Committee) were incubated with 25 μl of a mix of 
8 μg/ml of E. coli 0111:B4 LPS and graded concentrations of test compounds diluted 
in saline (typically serially diluted from 80 μM) for 15 minutes at 37oC. This resulted 
in final concentrations of 100 ng/ml of LPS and 1 nM of compound (at the lowest 
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dilution). Positive (LPS alone) and negative (saline) controls were included in each 
experiment. Erythrocytes were lysed and leukocytes were fixed in one step by mixing 
200 μl of the samples in 4 ml pre-warmed whole blood lyse/fix Buffer (Becton-
Dickinson Biosciences, San Jose, CA). After washing the cells at 500 x g for 8 
minutes in CBA buffer, the cells were permeabilized in ice-cold methanol for 30 min, 
washed twice in CBA buffer and transferred to a Millipore MultiScreen BV 1.2 μ 
filter plate and stained with either phycoerythrin (PE)-conjugated mouse anti-
p38MAPK (pT180/pY182; BD Biosciences) mAb, or a matched PE-labeled mouse 
IgG1 κ isotype control mAb for 60 minutes. The cells were washed twice in the plate 
by aspiration as per protocols supplied by the vendor. Cytometry was performed 
using a BD FACSArray instrument in the single-color mode for PE acquisition on 
20,000 gated events. Post-acquisition analyses were performed using FlowJo v 7.0 
software (Treestar, Ashland, OR).  
5.2.9 Multiplexed cytokine assay ex vivo in human blood: One hundred μl aliquots 
of fresh whole blood, anticoagulated with EDTA, obtained by venipuncture from 
healthy human volunteers with informed consent and as per guidelines approved by 
the Human Subjects Experimentation Committee, was exposed to an equal volume of 
20 ng/ml of E. coli 0111:B4 LPS, with graded concentrations of test compounds 
diluted in saline for 4 h in a 96-well microtiter plate.138,139 The effect of the 
compounds on modulating cytokine production was examined using a FACSArray 
multiplexed flow-cytometric bead array (CBA) system (Becton-Dickinson-
Pharmingen, San Jose, CA). The system uses a sandwich ELISA-on-a-bead 
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principle,140,141 and is comprised of 6 populations of microbeads that are spectrally 
unique in terms of their intrinsic fluorescence emission intensities (detected in the 
FL3 channel of a standard flow cytometer). Each bead population is coated with a 
distinct capture antibody to detect six different cytokines concurrently from biological 
samples (the human inflammation CBA kit includes TNF-α, IL-1β, IL-6, IL-8, IL-10, 
and IL-12p70). The beads are incubated with 30 μl of sample, and the cytokines of 
interest are first captured on the bead. After washing the beads, a mixture of optimally 
paired second antibodies conjugated to phycoerythrin is added which then forms a 
fluorescent ternary complex with the immobilized cytokine, the intensity (measured 
in the FL2 channel) of which is proportional to the cytokine concentration on the 
bead. The assay was performed according to protocols provided by the vendor. 
Standard curves were generated using recombinant cytokines provided in the kit. The 
data were analyzed in the CBA software suite that is integral to the FACSArray 
system. 
5.2.10 Mouse lethality experiments: Female, outbred, 9 to 11-week-old CF-1 mice 
(Charles River, Wilmington, MA) weighing 22-28 g were used as described 
elsewhere.137 The animals were sensitized to the lethal effects of LPS by D-
galactosamine.140;142;143 The lethal dose causing 100% mortality (LD100) dose for the 
batch of LPS used (E. coli 0111:B4; procured from Sigma) was first determined by 
administering D-galactosamine (800 mg/kg) and LPS (0, 10, 20, 50, 100, 200 
ng/mouse) as a single injection intraperitoneally (i.p.) in freshly prepared saline to 
cohorts of five animals in a volume of 0.2 ml. The expected dose-response profile 
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was observed in two independent experiments with all five mice receiving 100 ng 
succumbing within 24 h, establishing the LD100 dose to be 100 ng/mouse. In 
experiments designed to test dose-response effects of the acylhomospermines in 
affording protection against LPS-induced lethality, mice received graded doses of 
compound diluted in saline, i.p. in one flank, immediately before a supralethal (200 
ng) LPS challenge, which was administered as a separate i.p. injection into the other 
flank. Some animals also received test compounds subcutaneously or i.v. to observe 
differences in the degree and duration of protection; these experiments also served to 
verify that LPS was being sequestered systemically, and not just in situ, in the 
peritoneal cavity. In experiments in which the temporal window of protection was to 
be examined, a fixed dose of 200 μg/mouse of compound was administered at various 
times, before or after supralethal (200 ng/mouse) LPS challenge. Lethality was 
determined at 24 h post LPS challenge. 
5.2.11 Animal protocols for pharmacokinetic experiments: Female, outbred, 9 to 
11-week-old CF-1 mice (Charles River, Wilmington, MA) weighing 31-33 g were 
used as described elsewhere.137 Upon arrival, the mice were allowed to acclimatize 
for a week prior to experimentation, housed five per cage in a controlled environment 
at the AALAC-accredited University of Kansas Animal Care Facility, and allowed 
access to mouse chow and water ad libitum. All experimental procedures were 
performed in compliance with IACUC-approved animal protocols. 17 was solubilized 
in human serum albumin (5g/100 ml in sterile physiological saline). A total volume of 
0.2 ml was injected i.p. at a concentration of 1.25 mg/ml such that the dose was 250 
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μg/animal (6 mg/kg). This dose had conferred full protection against LPS-induced 
lethality.144   Mice (n = 55) were exsanguinated by terminal cardiac puncture under 
anesthesia at eleven different time points ranging from 5 to 1440 minutes following 
17 dosing. Plasma was isolated by centrifugation at 3000 rpm and stored –80°C. 
Adult male Sprague-Dawley rats (n = 4), precannulated with indwelling catheters in 
the carotid artery and jugular vein for sampling and dosing, respectively, and were 
housed during the experiment in rat metabolic cages of a Culex Automated 
Pharmacology System (Bioanalytical Systems Inc., West Lafayette, IN).145,146 The 
animals were injected i.v. via the jugular vein cannula with a dose of 12 mg/kg of 17. 
80 μl blood samples were collected at pre-programmed intervals from the carotid 
artery by the Culex system, and stored temporarily on the onboard MD-1202 fraction 
collector at 4oC. Plasma was obtained by centrifugation at 3000 RPM and stored at -
80oC. 
5.2.12 Liquid-liquid extraction of plasma samples and MS-MS Quantitation: To 
50 μl of plasma was sequentially added 10 μl of 10 μg/ml stock of the internal 
standard (17-D2), 20 μl of acetonitrile, followed by 100 μl of ammonium hydroxide 
in a polypropylene microfuge tube. One ml of ethylacetate was then added, vortexed 
for 5 minutes and centrifuged at 13000 g for 5 minutes. The organic phase was then 
removed, transferred to a fresh set of microfuge tubes, evaporated to dryness using a 
vacuum evaporator, reconstituted in 0.1 ml of 30% acetonitrile, and placed in the 
autosampler of the LC-MS instrument. Fractionation of the sample was performed on 
a Shimadzu Prominence LC using a Zorbax SB 2.1 mm x 50 mm stable-bond C18 
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reverse-phase column with a ten-minute binary gradient (CH3CN/Water, 0.1% 
HCOOH) from 15% to 95% of CH3CN. MS/MS was performed using a Sciex API 
3200 Triple Quadruple spectrometer for the 484.5 amu (17) and 486.5 amu (17-D2) 
parent ions with MS/MS quantization on a 112 amu daughter ion. Replicate sets of 
standards, and sample blanks were included in each run. The use of polypropylene 
material was crucial since 17 was found to strongly adhere to even siliconized glass. 
The assays were calibrated separately using mouse and rat plasma samples spiked 
with graded quantities of 17, and a fixed concentration (1000 ng/ml) of 17-D2. The 
ratios of analyte to the deuterated internal standard were used to construct the 
standard curves. Using the optimized liquid-liquid extraction procedure, an extraction 
ratio of 48% was obtained with excellent linearity (R=0.998), dynamic range (2-2500 
ng/ml), and precision (CV < 4%) at low ng/ml concentrations. 
5.2.13 Pharmacokinetic Analyses: Non-compartmental PK parameters were 
estimated from 17 plasma concentrations using PK Solutions 2.0 (Montrose, CO). 
The elimination rate constant (k) was computed by linear regression of the terminal 
concentration-time data, and the half-life (t½) was calculated as 0.693/k. Exponential 
terms for absorption and distribution, where relevant, were obtained by the method of 
residuals. The trapezoidal method was used to calculate the area under the time-
concentration curve from 0 to the time of last measurement (AUC0-t). AUC to infinity 
(AUC0-∞) was extrapolated by the summation of (AUC0-t) with the quotient of Cp/k, 
Cp being the last measured plasma 17 concentration. The volume of distribution (Vd) 
was estimated as Cl/k, where clearance (Cl) was obtained from dose / (AUC0-∞).  
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